Archive for December, 2019
Youngevity International (NASDAQ: YGYI, YGYIP), a leading multi-channel lifestyle company, today announced the pricing of its underwritten public offering of 245,398 shares of its 9.75% Series D Cumulative Redeemable Perpetual Preferred Stock at a price to the public of $22.75 per share. Youngevity expects approximately $5.58 million in gross proceeds from the offering, from which it intends to use the net proceeds for working capital and other general corporate purposes. The closing of the offering, subject to the satisfaction of customary conditions, is expected to occur on or about December 20, 2019. The shares of Series D Preferred Stock trade on the Nasdaq Capital Market under the symbol “YGYIP” and will not be convertible into or exchangeable for any of the company’s other securities. The Benchmark Company, LLC is acting as sole book-running manager of the offering.
To view the full press release, visit http://cnw.fm/SAyZ4
About Youngevity International, Inc.
Youngevity International, Inc. (NASDAQ: YGYI, YGYIP), is a multi-channel lifestyle company operating in three distinct business segments including a commercial coffee enterprise, a commercial hemp enterprise, and a multi-vertical omni direct selling enterprise. The company features a multi country selling network and has assembled a virtual Main Street of products and services under one corporate entity. YGYI offers products from the six top selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, apparel/jewelry, as well as innovative services. For investor information, please visit www.YGYI.com.
NOTE TO INVESTORS: The latest news and updates relating to YGYI are available in the company’s newsroom at http://cnw.fm/YGYI
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced the extension of its secured promissory note. According to the update, the note’s maturity date was extended from December 31, 2019 to March 31, 2020. In addition, the outstanding principal amount of the note was increased by $120,000 to a current principal amount of $2,029,104. Predictive Oncology issued 15,000 shares of common stock to the investor in connection with certain amended terms.
To view the full press release, visit http://nnw.fm/wODE0
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through five segments (Domestic, International, Clinical, CRO and DCHIP), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (D- CHIP) to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
According to the Marijuana Business Factbook, the cannabis industry could be worth $77 billion by 2022. Analysts at Arcview Market Research and BDS Analytics see worldwide sales of $55 billion by 2024. All as people around the world wake up to the health benefits of cannabis, including the treatment of insomnia, stress and anxiety. On top of that, 14% of Americans are now using products that contain CBD, according to a Gallup poll, as retailers rush to keep up with demand. As excitement builds, it’s opening a range of opportunity for cannabis companies including The Yield Growth Corp. (CSE:BOSS) (OTC:BOSQF), Canopy Growth Corporation (TSX:WEED) (NYSE:CGC), Charlotte’s Web Holdings Inc. (OTC:CWBHF) (CN:CWEB), OrganiGram Holdings Inc. (TSXV:OGI)(NASDAQ:OGI), and cbdMD Inc. (NYSE:YCBD).The Yield Growth Corp. (CSE:BOSS)(OTCQB:BOSQF) BREAKING NEWS: The Yield Growth Corp. just announced that the website to support sales of Wright & Well topical products in the state of Oregon has been launched at www.wrightandwellplus.com. Wright & Well consists of an Ayurveda-inspired collection of THC- and CBD-infused products. Using high quality Cannabis Sativa (Hemp) Root Oil, crafted through an exclusive proprietary extraction process, Wright & Well’s first five products, manufactured at Oregon licensed facility Nova Paths, have passed all regulatory requirements of the Oregon Liquor Control Commission (OLCC), including the completion of control studies of the final product. The products include THC and CBD infused massage oil, topical gel, and balm and two CBD tinctures. To support the sales of the Wright & Well product line through Oregon licensed distributor Nova Paths, Yield Growth has developed a sophisticated marketing plan for the Oregon market that focuses on the frontline sales team, instore experience and budtenders. Wright & Well products will also stand out with unrivaled packaging and in-store displays. The combined attention to education, packaging and displays is part of an overall strategy designed to support strong sales. The new Wright & Well website is striking and streamlined, and provides visitors with user-friendly experience. Customers can learn about the Wright & Well collection, ingredients and usage—making it easy to select products. Yield Growth’s U.S. subsidiary W&W Manufacturing Inc., is currently developing a CBD from hemp product line with a CBD online marketplace for planned launch in early 2020.Other cannabis-related developments from around the markets include:
Canopy Growth Corporation (TSX:WEED)(NYSE:CGC) just announced that effective January 14, 2020, David Klein has been appointed as the Company’s Chief Executive Officer. David brings a wealth of expertise to this role, having served in a number of senior leadership capacities over the past 14 years at Constellation Brands. His capabilities include extensive CPG and beverage alcohol industry experience, strong financial orientation, and experience operating in highly regulated markets in the U.S., Canada, Mexico and Europe. David is an experienced strategist with a deep understanding of how to build enduring consumer brands while leveraging operational scale across a dispersed production footprint. He is a strong leader with a proven track record of developing diverse and high performing teams. In his current role as executive vice president and chief financial officer at Constellation Brands, David oversees all aspects of the company’s finance operations, all mergers and acquisitions, as well as the company’s information technology function. He is widely respected among members of the U.S. investment community, earning recognition as a top CFO by Institutional Investor magazine the past three years. David serves as a member of Constellation Brands’ executive management committee. He has served on the Canopy Growth Board of Directors for over a year and is presently Canopy Growth’s Board Chair. This familiarity with the Company’s current leadership team and strategy will allow David to integrate quickly, a major benefit in the fast-moving cannabis sector.
Charlottes Web Holdings Inc. (OTC:CWBHF)(CN:CWEB) announced that it has closed its previously announced underwritten public offering for aggregate gross proceeds to the Company of C$66,250,000. A total of 5,000,000 units of the Company, at a price of C$13.25 per Unit were sold pursuant to the Offering. The Offering was led by Canaccord Genuity Corp., together with a syndicate of underwriters including Cormark Securities Inc., Eight Capital, and PI Financial Corp. Each Unit was comprised of one common share of the Company and one half of one common share purchase warrant. Each Warrant will be exercisable to acquire one common share for a period of 2 years following the closing date of the Offering at an exercise price of C$16.50 per Warrant Share, subject to adjustment in certain events. Charlottes Web has also granted the Underwriters an option to purchase up to 750,000 additional Units of the Company on the same terms as the Offering, exercisable within 30 days of the closing of the Offering. Net proceeds from the Offering will be used primarily to fund the Company’s business development and for general working capital purposes. The Units were offered in each of the provinces of Canada, other than Quebec, pursuant to the Company’s base shelf prospectus dated April 8, and were also offered by way of private placement in the United States to “qualified institutional buyers”. The terms of the Offering are described in a prospectus supplement dated November 27, 2019.
OrganiGram Holdings Inc. (TSXV:OGI)(NASDAQ:OGI) announced that the Company has received Health Canada’s approval for the licensing of 16 additional cultivation rooms under the Cannabis Regulations. The expanded license was effective as of December 12, 2019. The new cultivation rooms represent approximately 13,000 kg/yr1 of increased target cultivation capacity. These are the remaining 16 rooms licensed within the Company’s Phase 4B expansion and now brings the Company’s Moncton campus licensed capacity to a target of 89,000 kg/yr. As a result of this approval, cannabis plants will be moved into these new rooms on a rolling basis in early 2020. The Company anticipates initial harvesting of product from these new rooms by the end of April 2020 assuming normal cultivation timelines. After drying and other post-harvest processing (including packaging and product testing) dried flower from these additional rooms is expected to begin to be available for sale to patients and customers in the Company’s fiscal quarter ending May 31, 2020.
cbdMD Inc. (NYSE:YCBD) reported more than 12,300 online orders were received through its ecommerce site cbdMD.com during the Black Friday and Cyber Monday holiday sales period, which started Thursday, November 28, 2019 and ended Monday, December 2, 2019. This was the most online orders during any 5 consecutive day period in the company’s history. The average gross sales amount was $88.70 per order, after discounts and promotions. “cbdMD ranks highest in terms of overall consumer satisfaction as well as the highest in unaided consumer awareness of any of the top 20 CBD brands, according to a recent survey by the Brightfield Group. We continue to scale our online business, as well as add to our retail distribution, which is now over 4,000 stores. We believe we are incredibly well positioned for continued growth going into 2020,” said Martin Sumichrast, Chairman and Co-CEO of cbdMD.
Legal Disclaimer / Except for the historical information presented herein, matters discussed in this article contain forward-looking statements that are subject to certain risks and uncertainties that could cause actual results to differ materially from any future results, performance or achievements expressed or implied by such statements. Winning Media which has a partnership with www.MarijuanaStox.com is not registered with any financial or securities regulatory authority and does not provide nor claims to provide investment advice or recommendations to readers of this release. For making specific investment decisions, readers should seek their own advice. Winning Media, which has a partnership with www.MarijuanaStox.com, is only compensated for its services in the form of cash-based compensation. Pursuant to an agreement between Winning Media (partners of www.MarijuanaStox.com) and The Yield Growth Corp., Winning Media has been paid three thousand five hundred dollars for advertising and marketing services for The Yield Growth Corp. We own ZERO shares of The Yield Growth Corp. Please click here for full disclaimer.
Contact Information:
2818047972
ty@MarijuanaStox.com
December 17, 2019
Democrats in Congress have abandoned two marijuana proposals that were veteran-based and previously approved by Congress as part of their large-scale defense bill.
The House approved its version of the National Defense Authorization Act (NDAA) this summer. The legislation had several changes that would prevent the United States Department of Veteran Affairs from denying the veterans’ home loans applications due to their employment status in the legal marijuana sector.
The bill had another policy that would have allowed the military branches to reenlist service members convicted of single simple marijuana offenses.
However, the Senate did not have similar proposals in their legislation, but the leaders from the two bodies agreed to scrap some of the additional policies during the negotiations.
The Democrats did not cede on all the amendments that were not similar to the House legislation; but, both parties made compromises on the amendment proposals where the House withdrew about 630 provisions while the Senate ceded approximately 600.
The House conference negotiators did not view the marijuana measure as a priority. However, according to the sponsors of the bill, marijuana policies were to be prioritized as they represented urgent needs for the veterans and service members.
The home loan amendment provisions were made by Rep. Katherine Clark (D-MA). In May, Clark circulated a sign-on letter addressed to Veteran Affairs. The letter raised the issue and noted that a veteran in her district was denied home loan benefits because he was working in the marijuana industry.
The reenlistment waiver proposal was sponsored by Rep. Ruben Gallego (D-AZ). During a committee hearing in June, Gallego stressed that the country needs to think about military enlistment policies regarding marijuana felonies, especially looking at the recruitment crisis.
Gallego further said that the country’s views on marijuana consumption are changing, and the military has adjusted its recruitment process. He also noted that where necessary, the military can grant waivers to former simple marijuana convicts who want to serve their country.
According to a summary of the legislation, the House conference negotiators agreed on a bill funding “drug interdiction and counter-drug activities” by giving them $1 billion. The bill also calls for an assessment of the impact of any planned border wall construction would have on the quantity of narcotics entering the U.S. The bill includes the Fentanyl Sanctions Act, which puts in place several economic and financial sanctions to cease the operation of international opioid traffickers.
It is uncertain if the House Democrats will fight for the marijuana reform language in the appropriations negotiations. The current temporary spending legislation expires on December 20, and their goal is to finalize the full 2020 Fiscal Year appropriation before the expiration date.
In June, Rep. Earl Blumenauer (D-OR) withdrew a policy that would have permitted Veteran Affairs to prescribe medical marijuana to military veterans during the House consideration of the VA appending bill.
Analysts believe that cannabis industry actors, such as HTC Extraction Systems (TSX.V: HTC) (OTCQB: HTPRF) and Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), may not be too pleased that veterans will continue to be victimized for their involvement in state-legal marijuana programs.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
Sigma Labs Inc. (NASDAQ: SGLB), a leading developer of quality assurance software for the commercial 3D printing industry, recently announced its appointment of industry veteran Mark K. Ruport to the position of executive chairman and as a member of its board of directors. The appointment, which took effect December 3, 2019, is expected to play a key role in the company’s ongoing efforts to accelerate growth and increase shareholder value.
In total, Ruport brings more than three decades of public and private company experience in the software sector to Sigma Labs. His prior roles include executive leadership positions with Content Analyst Company, a leading developer of advanced analytics software that was acquired by its largest customer in 2017, and Configuresoft, a venture-backed Enterprise Systems Management company for which Ruport orchestrated an OEM contract that later led to the acquisition of the firm by EMC.
“As evidenced by the recent progress with OEMs, end users and additive manufacturing integrators, our business is now at an inflection point that requires an industry veteran to amplify our success and accelerate our market penetration alongside strategic partners with a keen interest in our technology,” John Rice, CEO of Sigma Labs, stated in the news release. “Mr. Ruport’s long history of taking companies through various stages of growth will be invaluable as we enter the next phase of our growth cycle. We believe there is significant potential for shareholder value creation and look forward to unlocking this for our shareholders under Mark’s leadership.”
To view the full press release, visit http://nnw.fm/i9aS0
About Sigma Labs
Sigma Labs, Inc. (NASDAQ: SGLB) is a leading provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D® brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (CAI) solutions known as PrintRite3D® for 3D advanced manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling non-destructive quality assurance mid-production, uniquely allowing errors to be corrected in real-time. For more information, visit the company’s website at www.SigmaLabsInc.com
NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://nnw.fm/SGLB
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
December 17, 2019
Earlier this year, a New Yorker was arrested and slapped with federal drug trafficking charges after the police intercepted and confiscated what they thought was a shipment of marijuana.
Ronen Levy was receiving the shipment of hemp from Vermont on his brother’s behalf, Oren Levy, who owns Green Angel CBD. Acting from a tip from a FedEx driver, New York police arrested him and confiscated 106 pounds of hemp.
On Tuesday, Brooklyn prosecutors dropped criminal charges against Levy, and he and his brother are seeking $10 million in damages from the NYPD. The claims include $8 million for false arrest, false imprisonment and other charges levied against Ronen Levy. They are also seeking $2 million for the confiscated hemp.
According to Oren Levy, even if he does get his hemp back, it would have deteriorated in quality to the point that it’s unusable.
At the moment, New York is undergoing a lot of legislative changes concerning marijuana, and that accounted for the Brooklyn prosecutors’ inability to give a ruling in time.
Brooklyn District Attorney Eric Gonzalez dropped the case against Ronan Levy on Tuesday, and he acknowledges that the hemp contained less than 0.06% THC in accordance with federal regulations.
Although the marijuana and hemp plant are quite similar in appearance, federal law makes a distinction based on THC levels. According to the 2018 Farm Bill, cannabis with less than 0.3% THC (delta-9 tetrahydrocannabinol) is classified as legal industrial hemp. The legislation gave farmers in all states and tribes liberty to farm industrial hemp under state and tribal programs.
Just this week, New York Governor Andrew Cuomo signed into law a bill that sets up a comprehensive regulatory system for growing and processing hemp. According to DA Gonzalez, the new regulations don’t address the fact that criminal law still classifies the cannabis plant as marijuana regardless of THC levels.
Sanford Rubenstein, an attorney known to take high profile police brutality cases, says a win for the brothers would send a clear and loud message that if you don’t follow the appropriate procedures and you don’t follow the paperwork and you mistake hemp for marijuana, your municipality will pay damages to the victim.
“Police departments have to be properly trained to know the difference between hemp and marijuana,” he adds.
Jahala Dudley of Fox Holler Farm grew and sold Oren Levy the hemp in dispute, and he is keeping an eye on the case. He sold the hemp for $17,000, and he estimates it could have sold for up to $60,000 in retail.
“I would like to know what happened to my hemp. That’s a product that I grew and was paid for.”
Industry watchers think the entire hemp industry, including Dama Financial and Canopy Rivers Inc. (TSX: RIV) (OTC: CNPOF), is following the New York case since its outcome could potential make law enforcement across the country more careful when confiscating hemp shipments.
About HempWireNews
HempWireNews (HWN) is a dedicated information provider focused on (1) aggregating hemp-related news, (2) issuing HempNewsBreaks designed to update investors on the latest developments in the hemp market, (3) enhancing corporate news releases, (4) providing full-service distribution and social media offerings to public and private client-partners and (5) designing and implementing all-inclusive corporate communication solutions. HNW is strategically positioned within the rapidly expanding hemp sector with a team of journalists working to help a growing roster of public and private companies reach a wide audience of investors, consumers and members of the media. We leverage a vast network of more than 5,000 key syndication outlets to deliver unparalleled visibility, recognition and content to the hemp industry. HempWireNews (HWN) is where HEMP news, content and information converge.
To receive instant SMS alerts, text HEMPWIRE to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.HempWireNews.com
Please see full terms of use and disclaimers on the HempWireNews website applicable to all content provided by HNW, wherever published or re-published: https://www.HempWireNews.com/Disclaimer
Do you have a questions or are you interested in working with HWN? Ask our Editor
HempWireNews (HWN)
Denver, Colorado
www.HempWireNews.com
303.498.7722 Office
Editor@HempWire.net
HempWireNews is part of the InvestorBrandNetwork.
December 16, 2019
- Several parties have indicated interest in potential acquisition of POAI’s Skyline Medical division
- The division has seen recent success with growing sales of its patented, FDA-approved STREAMWAY System
- POAI also regained compliance with Nasdaq’s minimum bid price requirement
Predictive Oncology Inc. (NASDAQ: POAI), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has revealed that several parties have indicated interest in the potential acquisition of Skyline Medical, the division of the company that produces and sells the STREAMWAY System (http://nnw.fm/u9Acn). The patented, FDA-approved STREAMWAY System is the first truly continuous, direct-to-drain fluid disposal system designed specifically for medical applications.
In the past several months, Skyline Medical has seen marked success with the system, including the completion of the sale of 10 systems to the foremost teaching and research hospital in upstate New York (http://nnw.fm/j1RdT). The sale surpasses the company’s largest single-hospital sale to date and is only one indication of Skyline Medical’s focus on making significant inroads in the U.S. market and expanding sales globally.
“I am exceptionally pleased with the rapid growth and development of our Helomics and Tumor Genesis divisions, as well as the multiple indications of interest for our Skyline Medical division,” POAI CEO Dr. Carl Schwartz stated in a news release. “If this results in the sale of Skyline Medical, it would not only provide additional working capital, it would also allow Predictive Oncology to focus on the further development and commercialization of our two divisions focused on precision medicine.”
Previously POAI had announced that it will be focusing primarily on the mission of applying artificial intelligence to precision medicine and drug discovery, sending a message to the market that its Skyline Medical division may be available. Updates on the future of the division may come in early 2020 as POAI evaluates options that will produce the greatest value for its stockholders. Although the company has received indications of interest, company officials note that there is no assurance that acceptable offers will be received or that a definitive agreement or sale will be completed.
In other POAI news, the company announced that it has regained compliance with Nasdaq’s minimum bid price requirement (http://nnw.fm/bOe4u). The company recently received a notification letter indicating the change in status. In November 2018, POAI was notified that the company did not meet the minimum price bid requirement. In order to meet the requirement, the letter stipulated that the closing bid price for POAI needed to be at least $1.00 for 10 consecutive business days. That occurred from October 29, 2019, to November 11, 2019, resulting in POAI regaining compliance.
Predictive Oncology, which began as a joint venture between Skyline Medical and Helomics, is ideally positioned to harness the power of artificial intelligence and work alongside the pharmaceutical, diagnostic and biotech industries to develop highly customizable assessment methods for cancer patients.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
December 16, 2019
- Several parties have indicated interest in potential acquisition of POAI’s Skyline Medical division
- The division has seen recent success with growing sales of its patented, FDA-approved STREAMWAY System
- POAI also regained compliance with Nasdaq’s minimum bid price requirement
Predictive Oncology Inc. (NASDAQ: POAI), a company focused on applying artificial intelligence to personalized medicine and drug discovery, has revealed that several parties have indicated interest in the potential acquisition of Skyline Medical, the division of the company that produces and sells the STREAMWAY System (http://nnw.fm/u9Acn). The patented, FDA-approved STREAMWAY System is the first truly continuous, direct-to-drain fluid disposal system designed specifically for medical applications.
In the past several months, Skyline Medical has seen marked success with the system, including the completion of the sale of 10 systems to the foremost teaching and research hospital in upstate New York (http://nnw.fm/j1RdT). The sale surpasses the company’s largest single-hospital sale to date and is only one indication of Skyline Medical’s focus on making significant inroads in the U.S. market and expanding sales globally.
“I am exceptionally pleased with the rapid growth and development of our Helomics and Tumor Genesis divisions, as well as the multiple indications of interest for our Skyline Medical division,” POAI CEO Dr. Carl Schwartz stated in a news release. “If this results in the sale of Skyline Medical, it would not only provide additional working capital, it would also allow Predictive Oncology to focus on the further development and commercialization of our two divisions focused on precision medicine.”
Previously POAI had announced that it will be focusing primarily on the mission of applying artificial intelligence to precision medicine and drug discovery, sending a message to the market that its Skyline Medical division may be available. Updates on the future of the division may come in early 2020 as POAI evaluates options that will produce the greatest value for its stockholders. Although the company has received indications of interest, company officials note that there is no assurance that acceptable offers will be received or that a definitive agreement or sale will be completed.
In other POAI news, the company announced that it has regained compliance with Nasdaq’s minimum bid price requirement (http://nnw.fm/bOe4u). The company recently received a notification letter indicating the change in status. In November 2018, POAI was notified that the company did not meet the minimum price bid requirement. In order to meet the requirement, the letter stipulated that the closing bid price for POAI needed to be at least $1.00 for 10 consecutive business days. That occurred from October 29, 2019, to November 11, 2019, resulting in POAI regaining compliance.
Predictive Oncology, which began as a joint venture between Skyline Medical and Helomics, is ideally positioned to harness the power of artificial intelligence and work alongside the pharmaceutical, diagnostic and biotech industries to develop highly customizable assessment methods for cancer patients.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
Is the beaten-down cannabis producer a better buy than the uplifted retailer?
It’s been a dismal year for marijuana stocks tied to large scale cannabis producers, but ancillary businesses that serve the industry are having a banner year. A lack of profits hasn’t stopped producers from outfitting their operations with products that ScottsMiracle-Gro (NYSE:SMG) has been eager to provide.
The first year of recreational sales in Canada wasn’t nearly as thrilling as investors had hoped, and Organigram (NASDAQ:OGI) looks like the only big producer that avoided a growth-at-any-cost strategy. The cannabis producer’s shares have lost 69% of their value since their peak in May, while ScottsMiracle-Gro is up about 65% in 2019.
Which one’s set up to climb further in the years ahead? Read on to find out.
The case for ScottsMiracle-Gro
For the past several years, ScottsMiracle-Gro has been plowing lawn and garden revenue into a new line of products for indoor gardeners. Sales from the company’s Hawthorne segment, which is geared toward the cannabis industry, have been more than a little disappointing until recently.
During the company’s fiscal year that ended on Sept. 30, Hawthorne segment sales jumped 95% higher than in the previous year. In 2018, ScottsMiracle Gro acquired one of the nation’s largest distributors of hydroponic products, Sunlight Supply. Adding this huge distribution channel pushed Hawthorne segment sales through the roof, and it could head higher.
It took a while, but Bayer (OTC:BAYRY) and ScottsMiracle-Gro have finally updated the Roundup marketing partnership Bayer inherited along with the rest of Monsanto. The German conglomerate recently agreed to buy four Roundup-brand product lines from Scotts for $112 million, and from now on, Scotts and Bayer will equally share future profits that could reach $15 million in fiscal 2019. In fiscal 2020, Scotts will also receive a larger share of profits derived from the consumer Roundup business, which should drive up its net commission received from Bayer by around $20 million annually.
Companywide, sales during fiscal 2019 increased 18% year over year thanks to contributions from Sunlight Supply, while sales, general, and administrative expenses rose just 11% over the same time frame.
Thanks to a better-than-expected performance, adjusted earnings in fiscal 2019 rose 20% to $4.47 per share. Unlike Organigram, ScottsMiracle-Gro shares profits with shareholders in the form of a dividend that offers a 2.3% yield at recent prices. Over the past year, Scotts used just 68% of free cash flow that operations generated to make dividend payments. That gives the company enough room to raise the payout at the same pace as its bottom line, which is being driven higher by indoor cannabis producers large and small.
The case for Organigram
In Canada, licensed producers and their disappointed shareholders are learning the hard way that raising lots of money is much easier than making any money in this low-margin business. Many of the largest businesses splurged to supply a recreational market that wasn’t exactly there yet.
While Canopy Growth, Aurora Cannabis, and their peers have been posting gigantic losses, Organigram looks like a well-managed business positioned to profit. Despite experiencing the same problems as its peers, adjusted earnings before interest, taxes, depreciation, and amortization, (EBITDA) reached 25% of net revenue, which worked out to CA$19.9 million during its fiscal year that ended Aug. 31.
Organigram’s still operating out of its first and only facility in Moncton, New Brunswick. There’s nothing necessarily wrong with operating multiple facilities, but it’s a lot harder to manage expenses from a distance.
Despite just one cultivation facility, Organigram can boast about a 10% share of Canada’s adult-use cannabis market. The company expects much higher revenue and lower operating expenses as a percentage of that revenue in 2020.
The better buy
Over the past decade, ScottsMiracle-Gro has provided a total return slightly lower than the S&P 500. Although Scotts will probably outperform the benchmark index in the coming decade, it’s already a $5.7 billion company, so huge gains probably aren’t possible. We’ve seen early signs that Scotts has finally figured out how to market products to the cannabis industry. Unfortunately, a chronically underperforming lawn and garden segment could lead to another long stretch of mediocre gains.
Although Organigram might not be the most talked-about marijuana stock in 2020, it could be the best performer in its industry thanks to ultra-low costs of production. That makes it the better buy right now, but tread lightly and watch for signs the company can keep meeting production goals as more retail outlets come online.
Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) is a global innovator in drug-delivery platforms focused on its patented DehydraTECH-based, drug-delivery technology and formulation development. A recent article discussing the company reads, “Earlier this year, Lexaria moved into its new head office that includes a Health Canada-licensed research and development laboratory that is being used to conduct world-leading research into drug-delivery methods and improvements. In addition to accelerating research in the company’s DehydraTECH drug-delivery platform, Lexaria is also considering issuing a limited commercial release of DehydraTECH version 2.0, which has been shown to deliver 811% more CBD into animal blood than generic industry control formulations, the company stated in an update to shareholders (http://cnw.fm/VV6qg). . . . Lexaria’s focus on pioneering new technologies that can more efficiently deliver APIs into the bloodstream, where they can have their desired effect, includes developing an effective way to cross the blood-brain-barrier. Lexaria’s DehydraTECH version 2.0 is showing promise in this arena as testing indicated 1,937% more CBD reached animal brain tissue compared to generic industry control formulations.”
To view the full article, visit http://cnw.fm/vP2lt
About Lexaria Bioscience Corp.
Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.
NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
December 13, 2019
If you have been paying attention to the news lately, you have undoubtedly heard of cannabidiol (CBD). Barely known a few years ago, it has exploded onto the medical, sports, health and wellness scenes, and with good reason too.
Chock-full of potent medicinal properties, the compound is said to be effective against a variety of diseases, ranging from high blood pressure and anxiety to chronic pain.
The 2018 Farm Bill was a catalyst, classifying cannabis with less than 0.3% THC (delta-9 tetrahydrocannabinol) as legal hemp and giving farmers in all states and tribes the green light to grow the lucrative cash crop under state and tribal programs.
Soon after, the American market for CBD products exploded. Tons of sellers streamed into the market, looking to cater to the immense demand. Discount retailer Dollar General is the latest to join the fray.
On Tuesday, the retailer announced that it will start selling at least 20 CBD products in over 1,000 stores in Tennessee and Kentucky.
“As with many of the products we carry in our stores, our decision to offer CBD products is based on customer interests or demands,” says Jason Reiser, Dollar General EVP, and Chief Merchandising Officer.
“At Dollar General, the customer is at the center of what we do, and the addition of CBD items is an extension of our ongoing commitment to providing customers with a curated and affordable assortment of products they seek.”
Dollar General joins an exclusive club of CBD sellers, including French luxury goods maker LVMH’s Sephora beauty chain, ULTA Beauty Inc. and American Eagle Outfitters Inc. who sell CBD-infused topicals. The discount retailer will sell an assortment of topicals including bath bombs, bath salts, and cosmetics, ranging from $7 to $20.
The variety store has also announced plans to expand its reach to Colorado, Florida, Indiana, South Carolina, Vermont, and Texas by spring next year to cater to the growing demand for CBD products.
The market for CBD-infused products has grown in leaps since industrial hemp was made legal, with the market worth at least $1 billion by 2018, and it is expected to hit at least $20 billion by 2026.
However, despite the plethora of products on the market, the U.S. Food and Drug Administration has repeatedly stated that it is illegal to market or sell CBD products as food additives, beverages and as a drug.
Before using any CBD-infused product, make sure you consult your doctor. This is the same advice that analysts have observed in the consumer education materials of CBD companies like Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) and Youngevity International Inc. (NASDAQ: YGYI). An informed consumer is an empowered one!
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.
- More funds available for the critical production ramp-up towards generating positive operating cash flow
- Interest only payments significantly reduce cash outflow
- Simpler capital structure
TORONTO, Dec. 13, 2019 – The Green Organic Dutchman Holdings Ltd. (the “Company” or “TGOD”) (TSX: TGOD) (US: TGODF), a leading producer of premium certified organic cannabis, is pleased to announce that the Company has entered into a binding term sheet with Maynbridge Capital Inc. (the “Lender”), subject to satisfactory documentation and the fulfilment of all conditions precedent, for a senior secured first lien credit facility of up to $41.7 million (the “Facility”). The Facility will replace the proposed mortgage loan as well as the sale and leaseback of its Ancaster Energy Centre, which are no longer being pursued by the Company at this time.
The Facility consists of a committed $26.7 million senior secured term loan (the “Loan”) with an 18-month term and 12 monthly interest only payments followed by 6 monthly payments of principal and interest, with the principal component based on a 15-year amortization, and an additional uncommitted $15.0 million senior secured term loan (the “Accordion Loan”), with terms to be agreed between the Lender and the Company. The interest rate on the Loan will be 13% per annum and the Loan will be secured by a first lien against all assets of the Company and its material subsidiaries. The Company will issue 7,000,000 common share purchase warrants of the Company (“Warrants”) to the Lender, subject to standard adjustment provisions, on the date of closing of the Loan. Each Warrant shall be exercisable to acquire one common share of the Company for a period of 36 months from closing of the transaction at an exercise price of C$1.00 per Warrant.
Upon closing of the Loan, TGOD will receive $26.7 million. A further $15 million may be made available by the Lender under the Accordion Loan upon the Lender’s credit approval and the achievement of certain operating and financial milestones, to be agreed, which the Company expects to obtain and achieve not earlier than the end of the third quarter of 2020.
The Loan’s gross proceeds of $26.7 million to be received on closing (which includes the financed portion of a fee in the amount of $1.7 million) compares to the combined total of $26 million that was expected in the first tranches of the mortgage loan and the sale and leaseback previously considered by the Company. In addition, the interest only payments under the Loan in the first-year amount to only $3.5 million in cash outflow, compared to a total of $7.1 million in cash outflow for interest and lease payments that would have been due under the mortgage loan and the sale and leaseback agreement. As such, this new lending arrangement represents a net positive for committed cash flow. The Company does not consider the difference in amounts from the Accordion Loan expected later in 2020 to impact the viability of the production ramp-up to operating cash flow by the second quarter of 2020.
The Loan is subject to completion of customary closing conditions, including satisfactory documentation, with expected completion of conditions precedent and closing on December 20, 2019 and in any event prior to December 31, 2019. The underwriter of the Company’s previously announced bought deal public offering of units has consented to the entering into of the Loan.
About The Green Organic Dutchman Holdings Ltd.
The Green Organic Dutchman Holdings Ltd. (TSX: TGOD) (US‐OTC: TGODF) is a premium certified organic cannabis company focused on the health and wellness market. Its certified‐organic cannabis is grown in living soil, as nature intended. The Company is committed to cultivating a better tomorrow by producing its products responsibly, with less waste and impact on the environment. Its two Canadian facilities are being built to LEED certification standards and its products are sold in recyclable packaging. In Canada, TGOD plans to expand its product portfolio by launching a series of next‐generation cannabis products such as organic teas, infusers and vapes. Through its European subsidiary, HemPoland, the Company also distributes premium hemp CBD oil in Europe. By leveraging science and technology, TGOD harnesses the power of nature from seed to sale.
TGOD’s Common Shares and warrants issued under the indenture dated November 1, 2017 trade on the TSX under the symbol “TGOD” and “TGOD.WT”, respectively. For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.
Cautionary Statements
This news release includes statements containing certain “forward‐looking information” within the meaning of applicable securities law (“forward‐looking statements”). Forward looking statements in this release includes, but is not limited to, statements about timing or likelihood of closing of the first tranche of the Facility and the ability to receive additional funds under the Facility, the ability of the Company to achieve certain operating cashflow conditions required by the Lender, the statement about the offering of any particular products by the Company in any jurisdiction and statements regarding the future performance of the Company. Forward‐looking statements are frequently characterized by words such as “plan”, “continue”, “expect”, “project”, “intend”, “should”, “believe”, “anticipate”, “estimate”, “may”, “will”, “potential”, “proposed” and other similar words, or statements that certain events or conditions “may” or “will” occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward‐looking statements throughout this news release. Forward‐looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties (including market conditions) and other factors that could cause actual events or results to differ materially from those projected in the forward‐looking statements, including those risk factors described in the Company’s most recently filed Annual Information Form available on SEDAR. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward‐looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither the TSX nor the TSX’s Regulation Services Provider (as that term is defined in the policies of Toronto Stock Exchange) accept responsibility for the adequacy or accuracy of this release.
SOURCE The Green Organic Dutchman Holdings Ltd.
SRAX (NASDAQ: SRAX), a digital-marketing and consumer data-management technology company, recently reported financial results for the three months ended September 30, 2019. An article discussing the company reads, “On the financial side, the company saw a vertical sales increase of 17% along with a net income of $1.4 million (http://nnw.fm/An1zq). These gains arose out of a critical quarter for the company that included multiple milestones, including a full integration for international users and the first steps in the process of offering BIGtoken in multiple languages. . . .Christopher Miglino spoke about the traction that the company’s platforms are gaining, noting that ‘sales from existing platforms grew 11% and 17%, for Q3 2019 compared to Q2 2019 and Q3 2018, respectively, and are already benefiting from advances in BIGtoken.’”
To view the full article, visit http://nnw.fm/B7e5K
About SRAX Inc.
SRAX is a digital-marketing and consumer-data-management technology company. SRAX’s technology unlocks data to reveal brands’ core consumers and the characteristics of those consumers across marketing channels. Monetizing its data sets, SRAX is growing multiple, recurring revenue streams through its various platforms. Through its BIGtoken platform, SRAX has developed a consumer-managed data marketplace where people can own and earn from their data, thereby offering everyone in the internet ecosystem choice, transparency and compensation. SRAX’s tools deliver a digital competitive advantage for brands in the CPG, automotive, investor-relations, luxury and lifestyle verticals by integrating all aspects of the advertising experience, including verified consumer participation, into one platform. For more information, visit the company’s website at www.SRAX.com.
NOTE TO INVESTORS: The latest news and updates relating to SRAX are available in the company’s newsroom at http://nnw.fm/SRAX
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
Organigram Holdings (NASDAQ: OGI) (TSX: OGI), the parent company of Organigram Inc. (the “company” or “Organigram”), a leading licensed producer of cannabis, today announced the company’s receipt of Health Canada’s approval for the licensing of 16 additional cultivation rooms under the Cannabis Regulations. According to the update, the expanded license was effective as of December 12, 2019, and the new cultivation rooms represent approximately 13,000 kg/yr1 of increased target cultivation capacity. “This is a dynamic time for Organigram and the industry as a whole. Cannabis 2.0 – the legalization of adult use recreational cannabis edibles, vape products, extracts and topicals – is a new era for cannabis here at home and around the world,” Organigram CEO Greg Engel said in the news release. “Our physical expansion reflects our ambitious response to this new opportunity as well as our ongoing commitment to anticipating and meeting the demands of Canadian cannabis consumers for new and innovative cannabis experiences.”
To view the full press release, visit http://cnw.fm/hQ8gF
About Organigram Holdings Inc.
Organigram Holdings Inc. is a NASDAQ Global Select and TSX listed company whose wholly owned subsidiary, Organigram Inc., is a licensed producer of cannabis and cannabis-derived products in Canada. Organigram is focused on producing high-quality, indoor-grown cannabis for patients and adult recreational consumers in Canada, as well as developing international business partnerships to extend the Company’s global footprint. Organigram has also developed a portfolio of legal adult use recreational cannabis brands including The Edison Cannabis Company, Ankr Organics and Trailblazer. Organigram’s primary facility is located in Moncton, New Brunswick and the Company is regulated by the Cannabis Act and the Cannabis Regulations (Canada). For more information, visit the company’s website at www.Organigram.ca.
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
December 13, 2019
- POAI sees Q3 2019 revenue total $522,696 from $329,930 in Q3 2018
- Company reports records sales of proprietary systems, supplies
- Significant business highlights indicate continued momentum as Predictive Oncology looks to bright future
Predictive Oncology Inc. (NASDAQ: POAI), an artificial intelligence (AI) and data-driven functional precision medicine company, released its financial results for Q3 2019, and the numbers are impressive, including quarter revenues increasing 58% year over year (http://nnw.fm/7Qp5g). The company also provided a business update outlining significant highlights reached during the quarter.
POAI reported that revenue for the quarter ended September 30, 2019, totaled $522,696, compared with $329,930 for the same period of 2018. Those numbers included revenue from record sales of the company’s STREAMWAY systems and disposable supplies. Predictive Oncology reported the sales of 19 STREAMWAY systems, a significant increase when compared to 10 sales of the system during the comparable period in 2018.
Cost of sales for Q3 2019 was $208,096 compared to $83,006 in the same period of 2018. Gross profit margin declined to 60% percent versus 75% in the third quarters of 2019 and 2018 respectively. Operating expenses for the quarter ended September 30, 2019, totaled $707,414 down from $723,939 for the third quarter of 2018. General and administrative expenses were $2,616,991 for Q3 2019, compared to $762,603 during Q3 2018. Sales and marketing expenses declined significantly, totaling $434,955 in Q3 2019 compared to $621,465 for the previous year.
In addition to the impressive numbers, POAI noted several Q3 2019 business highlights, including the following:
- Initial models in progress with Interpace Diagnostics for Thyroid
- Helomics has initiated pilot sequencing of 48 samples
- ChemImage working on additional validation utilizing POAI platform and AI (D-CHIP) in prostate cancer
- Specicare ‘Pioneer’ Precision Medicine trial in progress
- Predictive Oncology continues to execute on Cancer Quest 2020
- POAI subsidiary TumorGenesis has initiated the building of media kits to allow the growth of ovarian cancer cells in its labs.
- Clinically validated, patient-derived (PDx) tumor profiling platform to generate drug response profiles and multi-omic data
- Data on drug response profiles of more than 150,000 tumors across 137 cancer types using the PDx platform in more than 10 years of clinical testing.
“I am very pleased with the growth and development of our unique assets, Helomics and Tumor Genesis, and the increase in international interest in our Skyline products,” POAI CEO Dr. Carl Schwartz stated in a news release. “The future looks very bright.”
Predictive Oncology is committed to the mission of improving the standard of care for cancer patients through innovative, data-driven products and services. The company provides predictive models of tumor drug response to improve clinical outcomes for patients. POAI is at the vanguard of the latest scientific endeavors in cancer research to better understand the complexities of individual cancers and tailor individualized therapeutic protocols.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
December 12, 2019
- POAI subsidiary sequencing ovarian cancers as part of CancerQuest 2020 project, building largest ovarian multi-omic database in the world
- Company’s work designed to speed development of new drugs, provide therapeutic choices
- Helomics recently signed collaborative agreement with UPMC-Magee to establish data- and artificial-intelligence-driven approach to treating ovarian cancer
The power of artificial intelligence (AI) to assist in the detection of ovarian cancer much earlier than previously possible is being recognized worldwide. A company in the United Kingdom is touting the ability of AI to eliminate late detection of ovarian cancer, thanks to advancements in health-care technology (http://nnw.fm/beR20). The contribution AI is making in the detection of ovarian cancer has been a longtime, consistent focus for Predictive Oncology Inc. (NASDAQ: POAI) as well.
Predictive Oncology recently began sequencing ovarian cancers as part of its CancerQuest 2020 project and is building the largest ovarian multi-omic database in the world, designed to speed the development of new drugs and provide better therapeutic choices. Predictive Oncology’s subsidiary, Helomics, is vital to the CancerQuest2020 work POAI is doing in the ovarian cancer space.
Helomics currently has approximately 150,000 cases on its molecular information platform, 38,000 of which are specific to ovarian cancer. This invaluable scientific asset positions POAI as a leader in providing the critical molecular information needed for more effective patient treatments and new drug discovery.
As part of its CancerQuest 2020 project, Predictive Oncology, through Helomics, recently signed a collaborative agreement with UPMC-Magee to establish a data- and artificial-intelligence-driven approach to treating ovarian cancer. Based on the agreement, the partnership is designed to validate the significant value of using AI-powered decision-making for identifying specific treatments on specific genotypes to predict clinical outcomes for ovarian cancer patients.
Helomics has also begun sequencing retrospective ovarian cancer cases from the UPMC-Magee collaboration (http://nnw.fm/peQC8). As part of the sequencing process, Helomics is analyzing the mutations in the tumor (genome) and the expression of genes (transcriptome) in order to build a comprehensive multi-omic picture of the tumor. That information can then be brought together with Helomics’ data set of drug-response profiles to build an AI-driven predictive model of ovarian cancer.
“We believe the combination of the rich multi-omic profile of the tumor and clinical outcome data will allow us to build an AI-driven model of ovarian cancer capable of predicting the tumor drug response and patient outcome,” Helomics CTO Dr. Mark Collins stated in a news release.
In addition to its ovarian-cancer data, Helomics has another 120,000 tumors with drug-response data across 137 cancer types that include lung, breast, pancreatic, colon and head and neck. Moving forward, the company intends to sequence all the tumors and build out predictive models in these additional disease categories. Once this work is complete, Helomics will have the largest pan-cancer, multi-omic database with drug responses in the market.
For more information, visit the company’s website at www.Predictive-Oncology.com
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
The big day that we’ve all been waiting for is nearly here in Canada. Following the commencement of recreational cannabis sales on Oct. 17, 2018, and the implementation of regulations regarding marijuana derivatives exactly one year later (Oct. 17, 2019), we’re now just days away from these alternative consumption options officially hitting dispensary shelves.
There’s obvious excitement surrounding derivatives, such as edibles, vapes, and cannabis-infused beverages, among the investment community. But as you’ll see in a moment, it’s not all peaches and cream for marijuana stocks. With derivative sales about to kick off anytime now in Canada, here are five things you ought to know.
1. Not everything is getting a green light with this derivative launch
First of all, it’s important to recognize that the legalization of derivative products doesn’t mean it’s a free-for-all when it comes to alternative consumption options. Although consumers will now be able to purchase vapes, edibles, infused beverages, concentrates, topicals, and tinctures, cannabis infused with alcoholic beverages is still a no-no. That means Constellation Brands and Molson Coors Brewing, which are alcohol giants and have infused-beverage partnerships in the cannabis space, will have to focus their attention on nonalcoholic infused products.
Furthermore, the federal government set some concrete guidelines as to what tetrahydrocannabinol (THC) concentrations are allowed in derivatives — THC being the cannabinoid that gets users high. Edibles are only allowed to have 10 milligrams (mg) of THC in a single serving, while concentrates, topicals, balms, and oils will have limits of 1,000 mg of THC per package.
2. Derivatives are what will drive margins for years to come
Make no mistake about it, derivatives are the future of the cannabis industry. Not only are derivatives likely to speak to a younger generation of consumers, but they deliver significantly juicier margins than traditional dried cannabis flower. There’s not a marijuana company out there that isn’t devoting a good portion of its portfolio or production to these high-margin consumables.
For example, even though OrganiGram Holdings (NASDAQ:OGI) has been devoting most of its sales to the recreational market — adult-use consumers typically buy dried flower — it has quite the array of derivative products waiting to hit dispensary shelves. OrganiGram purchased 15 million Canadian dollars’ worth of fully automated equipment that’ll help the company produce up to 4 million kilos of chocolate edibles each year. It also has a nano-emulsification technology that it’ll be introducing as a powder next year that can be added to beverages. This formulation speeds up the process by which cannabinoids take effect. OrganiGram is even one of four chosen partners for the PAX Labs Era vaping device.
Derivatives are the key to long-term success for OrganiGram and the entire North American pot industry.
3. Supply issues in the derivative space will be persistent
Remember that not-so-great stuff I mentioned? Well, despite hitting dispensary shelves any day now, derivatives are going to face the same supply constraints that have plagued the Canadian marijuana landscape since day one of legalization in October 2018.
Thankfully, Health Canada is unlikely to be as much of a hindrance to derivatives reaching consumers as the regulatory agency has been with dried flower. The agency began the year with an enormous backlog of more than 800 cultivation, processing, and licensing applications, and has struggled to approve companies to grow, process, and sell weed in a timely manner.
The bigger issue here is the slow-stepped rollout of physical dispensaries in certain provinces. Ontario, which is home to 38% of Canada’s residents, had a meager two dozen dispensaries open at the one-year anniversary of adult-use weed sales. Even with a second round of dispensary licenses issued, the legal retail landscape in Canada’s most lucrative province for marijuana is inadequate. That’s what’s going to stop companies like Canopy Growth and Aurora Cannabis from succeeding right out of the gate.
4. Pricing pressures may rear their head early on
One of the oddest aspects of the supply issues that have persisted since day one is that they’ve actually led to the oversupply of product cropping up in select provinces. How’s that possible with demand in the legal market nowhere near satisfied? Well, with so few legal channels to sell product (i.e., with an inadequate number of open dispensaries), there’s been a bottleneck of supply in select provinces, thereby leading to falling cannabis prices.
It’s my suspicion that we’re only a few months away from seeing the same exact thing happen to derivative pot products. Remember, it took a couple of months before dried flower product supply had built up adequately in existing dispensaries, and we’re liable to see this same casual inventory buildup with derivatives. But without a quick means of licensing more retail stores in provinces like Ontario, the same oversupply pitfall awaits derivatives — and that’s a big problem considering the hefty margins they’re expected to provide.
5. Vape-related health concerns could subdue a top-selling consumption option
A fifth and final thing to be aware of is that Canada’s derivative launch could be marred by the vape-related health scare that’s popped up in the U.S. in recent months.
According to the Centers for Disease Control and Prevention (CDC), 2,291 confirmed or probable cases of e-cigarette, or vaping, product use-associated lung injury (EVALI) were reported, leading to 48 deaths. The CDC believes that vitamin E acetate is the culprit behind EVALI, with a majority of the instances tying into black-market product containing THC. As a result, the CDC cautions that consumers not vape liquids containing THC.
This advice is — pardon the pun — a clear blow to Cronos Group (NASDAQ:CRON), which expects to lean on its partnership with Altria Group to become a vape market share leader. When Altria became an equity investor in Cronos, the expectation is that Cronos would lean on Altria’s marketing expertise and product development prowess. But with fears over vaping safety clearly apparent, potentially the most lucrative derivative product, vaping, may have a subdued launch in Canada. As such, it’s probably a smart idea for all investors to continue to temper their expectations for Cronos Group and the entire pot industry.
NEW YORK, Dec. 12, 2019 — via NetworkWire — Sigma Labs Inc. (NASDAQ: SGLB) today announces the broadcast of its exclusive audio interview with NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) solution that delivers clients unparalleled visibility, recognition and brand awareness in the investment community.
The interview can be heard at http://nnw.fm/6F87x.
Sigma Labs President and CEO John Rice joins NNW’s Stuart Smith to discuss the Company’s disruptive technology. Sigma Labs is the only provider of in-process, quality-assurance software for the commercial 3D metal-printing industry that enables operators of machines making 3D metal parts to offset emerging quality problems, sustain part quality and avoid rejects.
Sigma Labs was created almost a decade ago by a group of senior scientists and engineers from Los Alamos Labs who wanted to develop revolutionary parts in metallurgy science. The Company’s original forays into the dental and ordnance sectors eventually resulted in a focus on 3D metal manufacturing, which Rice calls an important, transformative, disruptive technology.
“That’s an overused term,” Rice acknowledges, “but this is a disruptive technology. Today you can find a subassembly of 20 or 40 parts, and you can use 3D metal manufacturing to make that whole assembly as one part, and it can have very complex geometry and very high-performance standards. It is an absolutely unique way to build unique products.
“It will lead to a different configuration of how factories work in the future. You will not only have traditional factories with a whole line of manufacturing machines, but you will also have internet of things factories where, in the same way that the distribution of parts has been completely changed by Amazon and Walmart, so this technology can change the distribution of manufacturing. You will be able to have your doctor prescribe a new shoulder for you, someone designs it in Boston, pushes a button, and it is made in a machine across the street. It’s a really exciting technology.”
The challenge with 3D metal printing in the past, said Rice, is that it’s difficult to get 3D metal manufacturing machines to develop a high level of highly consistent, repeatable quality parts. However, Sigma’s technology allows the machines to be monitored in real-time as the parts are being made. “Our hardware/software package is observing and assessing what is going on in there, and we are able to extract from thermal information when a part is beginning to drift out of specification. We can spot the precursors of a quality problem. We can alert the machine operator, who can stop it and make a correction and save the part and very often save the build,” he said.
Even with the quality challenge, 3D metal printing is a billion-dollar market, but with Sigma Labs’ technology potentially solving the industry’s major roadblock, the potential is staggering. After a year of intense effort and work, Sigma Labs currently has six major enterprise companies—three OEMs and three end users—that in the next several months will be completing the test and evaluation phases of Sigma Lab equipment in their shops.
“2019 was about getting into the market,” Rice observed, “and 2020 is about harvesting the market.”
Listen to the full interview with Sigma Labs president and CEO John Rice at http://nnw.fm/6F87x
About Sigma Labs Inc.
Sigma Labs Inc. (NASDAQ: SGLB) is an emerging provider of quality assurance software to the commercial 3D printing industry under the PrintRite3D® brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time computer aided inspection (“CAI”) solutions known as PrintRite3D for 3D advanced-manufacturing technologies. Sigma Labs’ advanced, computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production, uniquely allowing errors to be corrected in real time. For more information, please visit www.SigmaLabsInc.com.
About NetworkNewsAudio
NetworkNewsAudio (NNA), a NetworkNewsWire (NNW) Solution, allows you to sit back and listen to market updates, CEO interviews and a Company AudioPressRelease (APR). These audio clips provide snapshots of position, opportunity and momentum. NetworkNewsAudio (NNA) can assist your company by cutting through the overload of information in today’s market, NNA brings its clients unparalleled visibility, recognition and brand awareness. NetworkNewsWire (NNW) is where news, content and information converge. NetworkNewsWire (NNW) is a comprehensive provider of news aggregation and syndication, enhanced press release services and a full array of social communication solutions. As a multifaceted financial news and distribution company with an extensive team of journalists and writers, NNW has the unparalleled ability to reach a wide audience of investors, consumers, journalists and the general public with an ever-growing distribution network of more than 5,000 key syndication outlets across the nation.
For more information, visit: www.NetworkNewsAudio.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer.
Forward-Looking Statements
This release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended and Section 21E of the Securities Exchange Act of 1934, as amended. All forward-looking statements are inherently uncertain as they are based on current expectations and assumptions concerning future events or future performance of the company. Readers are cautioned not to place undue reliance on these forward-looking statements, which are only predictions and speak only as of the date hereof. In evaluating such statements, prospective investors should review carefully various risks and uncertainties identified in this release and matters set in the company’s SEC filings. These risks and uncertainties could cause the company’s actual results to differ materially from those indicated in the forward-looking statements.
Corporate Communications:
NetworkWire (NW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkWire.com
December 12, 2019
Palm Beach, FL – December 12, 2019 — Cannabis could very well be the hottest buzzword of 2020. For one, we’re just beginning to see higher approval ratings for cannabis in the U.S. According to the Pew Research Center, 67% of Americans now support its legalization In addition, only 32% of adults now oppose legalization, as compared to 52% in 2010. Two, many more retailers are jumping on board. Neiman Marcus, Abercrombie & Fitch, Vitamin Shoppe, Kroger’s, Barney’s, DSW, CVS, American Eagle Outfitters, Sephora, Dick’s Sporting Goods, and even Dollar General will sell CBD products. Three, with U.S. presidential elections just months away, cannabis is becoming a hot platform topic. President Trump for example has said he would support bipartisan efforts in Congress to ease the federal ban on marijuana. That’s creating sizable opportunity for companies including Veritas Farms Inc. (OTCQB:VFRM), Aphria Inc. (NYSE:APHA)(TSX:APHA), Cronos Group Inc. (NASDAQ:CRON), Green Growth Brands Inc.(CSE:GGB)(OTCQB:GGBXF), and Curaleaf Holdings Inc. (CSE:CURA)(OTCQX:CURLF).
Veritas Farms Inc. (OTCQB:VFRM) BREAKING NEWS: Veritas Farms Inc. just announced that it has signed a lease for a 34,000 square foot product production and distribution facility in Aurora, Colorado. The new facility is located inside the Majestic Commercenter, a 1,500-acre master planned business park located just 5 miles from Denver International Airport, and will be used for production, warehousing, ecommerce fulfillment and commercial distribution of Veritas Farms’ ingestible and topical product lines. The facility will also house additional office and meeting space for the Company. “This new facility represents an important part of our overall growth strategy moving into 2020” explained Veritas Farms CEO Alexander Salgado “When we move in, we will be joining the likes of Amazon, Crate and Barrel, Airbus and other leading corporations in the business park, and the sites convenient location near the Denver International Airport, makes it an important step in the continuation of our overall growth strategy, which focuses on expanding our vertically integrated operations to meet rapidly rising consumer demand.” Veritas Farms will begin buildout work on the property as soon as possible and hopes to move into the new facility by the end of the 1st Quarter 2020. The expansion of operations follows aggressive customer acquisition campaigns undertaken by The Company, which management believes will support increasing sales during 2020.
Other cannabis-related developments from around the markets include:
Aphria Inc. (NYSE:APHA)(TSX:APHA) announced that its subsidiary Aphria Diamond secured a credit facility, on November 29 2019, with a major Canadian chartered bank as sole arranger, sole book runner and administrative agent on behalf of a group of lenders for a committed senior secured credit facility of $80 million. “Aphria has the largest cash balance in the cannabis industry without the dilution of a strategic partner,” said Irwin D. Simon. “We are pleased to have secured a term loan that will repatriate a portion of our investment in Aphria Diamond, to be strategically deployed by Aphria. This loan strengthens our balance sheet without being dilutive, and positions Aphria Diamond for success as we expand into new categories and growth opportunities in cannabis to enhance value for shareholders long term.” Since securing its Health Canada license on November 1, 2019, Aphria Diamond is quickly coming on scale. Aphria Diamond will be 70 per cent planted by mid-week, with 350,000 young seedlings planted. With the level of automation and scale of the facility, the Company anticipates Aphria Diamond to have one of the lowest cost structures in the industry. Aphria expects the dried flower production from the first harvest to be sold to provincial control boards sometime in March 2020.
Cronos Group Inc. (NASDAQ:CRON) announced its financial results and business highlights for the three- and nine-months ending September 30, 2019. “As demonstrated by our progress in the third quarter, we are making great strides to advance the development and diversity of our portfolio and to expand our manufacturing capabilities,” said Mike Gorenstein, CEO of Cronos Group. “We are confident that our platform strategy and focus on consumer driven innovation will continue to differentiate Cronos Group and drive growth and value creation over the long-term.”
Green Growth Brands Inc. (CSE:GGB)(OTCQB:GGBXF) reported its results for the thirteen-week period ended September 28, 2019. Revenues for the period totaled $12.7M. “As we approach the holiday shopping season, we are confident in our growth trajectory,” said Peter Horvath, CEO. “We are proud of the topline growth we accomplished in Q1 and are extremely pleased with our current results, which are an indication of future growth. In fact, the four weeks of fiscal November, retail CBD sales were two-thirds of our total CBD sales reported in all of the thirteen weeks of first quarter fiscal 2020, which we are reporting today. This topline growth is reflective of our shift from investing in the foundation of our CBD business to focusing on its execution. “In a very short-time we have grown a meaningful CBD footprint. We believe our products, network of shops, rapidly growing web business and wholesale relationships position us as a leader in the industry. In the coming quarters we look-forward to reporting similar trends and results for our MSO segment of the business. As we begin to reach scale our consumer and operations expertise will be clearly reflected, not only in the customer experiences we create and the loyalty we drive, but also in our financials as we work towards profitability.”
Curaleaf Holdings Inc. (CSE:CURA)(OTCQX:CURLF) announced that Joe Bayern will become President of Curaleaf Holdings, Inc., effective immediately. Bayern brings over 20 years of executive leadership experience in consumer packaged goods at a critically important moment in Curaleaf’s growth trajectory. He will report to Curaleaf CEO Joseph Lusardi. As President, Bayern will work closely with the senior executive team to lead the company and oversee its continued growth. Bayern will primarily be focused on driving operational excellence and executing on Curaleaf’s mission. Chief Executive Officer Joseph Lusardi will continue to oversee the strategic vision and operations of the company.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third- party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM expects to be compensated thirty five hundred dollars for news coverage of current press releases issued by Veritas Farms Inc., by a non-affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757
Industry veteran brings 40 year of experience to support CURE’s rapid growth
OXNARD, Calif., Nov. 19, 2019 — CURE Pharmaceutical (OTC: CURR), an innovative drug delivery and development company, today announced that it has named John K. Bell, FCA, FCPA, ICD.D to its board of directors. Bell brings more than 40 years of experience to the company, most recently serving as chairman of the Canopy Rivers board of directors and former chairman of Canopy Growth’s board of directors.
“John’s unparalleled depth and breadth of expertise makes him an invaluable asset to our growth strategy,” said Rob Davidson, CEO of CURE Pharmaceutical. “His impressive array of experience supports every aspect of our business, including pharmaceutical, manufacturing, financial and cannabis.”
Bell is a managing partner at Onbelay Capital Inc., a private equity and investment firm based in Cambridge, Canada. He has sat on a number of public boards, most recently with DelMar Pharmaceuticals, which develops new treatments for cancer. He also was the founder and CEO of Shred-Tech, Inc., a leader in the mobile shredding industry. He was the owner and CEO of Polymer Technologies Inc., a global manufacturer of auto parts. He has served as chairman and principal shareholder of fleet management company BSM Technologies Inc. (TSX-V) and was CEO and director of ATS Automation (TSX) and its 24 global manufacturing facilities.
“Safe and reliable delivery systems for cannabinoid molecules and related products are still in the early stages and CURE has the opportunity to maintain its global leadership in the industry due to its proprietary technologies, excellent research capabilities and strong management,” said Bell. “It is a tremendous opportunity to be part of this exceptionally talented team that is changing the future of medicine.”
Bell is also a philanthropist who has contributed to and provided leadership for numerous organizations including Cambridge Memorial Hospital, Waterloo Regional Police, Waterloo Region Prosperity Council, and Crohn’s and Colitis Canada and the Stratford festival.
About CURE Pharmaceutical
CURE Pharmaceutical® is a vertically integrated drug delivery and development company committed to improving drug efficacy, safety, and the patient experience through its proprietary drug dosage forms and delivery systems. CURE has a cGMP manufacturing facility and is a pioneering developer and manufacturer of CUREform™, a patented and proprietary oral delivery platform that includes CUREfilm®, one of the most advanced oral thin films on the market today and CUREpods™, a novel chewable delivery system. CUREform’s combined technologies provide opportunities for both immediate and controlled-release drug delivery of a wide range of active ingredients. CURE partners with biotech, pharmaceutical and wellness companies worldwide and has positioned itself to advance numerous therapeutic categories, including the pharmaceutical cannabis sector with partnerships in the U.S., Canada, Israel, and other markets. The company’s mission is to improve people’s lives by redefining how medicines are delivered and experienced.
For more information about CURE Pharmaceutical, please visit its website at www.curepharma.com.
Media Contact:
Paulo Acuña
pacuna@olmsteadwilliams.com
310.824.9000
December 11, 2019
On Friday, a bipartisan coalition of legislators from the House and Senate sent a letter to the Department of Justice requesting policy amendments, which would allow researchers to use marijuana bought from state-legal dispensaries for their studies on its benefits and risks.
The legislators were led by Rep. Harley Rouda (D-CA) and Sen. Brian Schatz (D-HI). In the letter, they cited federal health agencies’ feedback where they said that research on marijuana is inhibited by the existing restrictions on cannabis. The primary challenge is that there exists only one federally-authorized facility producing research-grade marijuana.
Although the DEA said that they are in the process of authorizing more manufacturers, three years have passed since they announced approving more research-grade marijuana growers. The same agency further noted that it is in the process of developing alternative rules for licensing submitted applications.
However, the National Institute of Health and the Food and Drug Administration released a status quo report that did not address the barriers inhibiting researchers from using marijuana obtained from dispensaries for their research. The letter recommends for the agencies to allow researchers to use marijuana acquired from the state-legal dispensaries.
The legislators wrote in their letter that many states have marijuana laws and regulations in place for licensing industrial manufacturing activities and products for medical marijuana but not for research purposes, which would lead to FDA licensure.
The letter also repeatedly pointed out the lack of chemical diversity of the marijuana supplied by the federal government. One study found that marijuana obtained from a national research facility is more similar to hemp than to cannabis found in the market.
The bipartisan coalition made two recommendations; the first one is the amendment of internal policy which would allow researchers with Schedule 1 licenses to obtain marijuana-derived products from state-legal dispensaries for study. The second one is to issue guidance clarifying that DEA licenses are not a must for hemp researchers and that they can obtain hemp since it was legalized under the 2018 Farm Bill across the U.S.
The DEA is required to issue a response to the letter by December 20.
Twenty-one members of Congress signed the letter, including Senators such as Kamala Harris (D-CA), Cory Gardner (R-CO), Earl Blumenauer (D-OR), Joe Kennedy (D-MA), and Matt Gaetz (R-FL).
In a press release, Rouda said that the U.S. research laws are ancient. He also noted that 47 states have some form of marijuana legalization, and the federal agencies must ensure that there is a way to study the benefits and risks of marijuana products.
In April, Attorney General William Barr received a similar letter requesting for an increase in the number of federally-approved cannabis cultivators.
It is widely believed that letters, such as the one written by these bipartisan lawmakers, no longer excite marijuana industry members like No Borders Inc. (OTC: NBDR) and Youngevity International Inc. (NASDAQ: YGYI) since no concrete action has so far resulted from such letters.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
December 11, 2019
- SGLB’s PrintRite3D Real-Time Melt Pool Analytics software platform drew attention of industry elite at top international event
- PrintRite3D version 5.2 contains new features, enhancements that further strengthen already impressive offering
- Rising attendance, interest in event demonstrates elevated importance of, new opportunities in additive manufacturing
Sigma Labs Inc.’s (NASDAQ: SGLB) exclusive, in-process quality-control platform for metal-additive manufacturing was featured at the SGLB booth at Formnext 2019, the industry’s premier global conference held November 19-22, 2019, in Frankfurt, Germany. SGLB, the leading developer of quality assurance software for the commercial 3D metal-printing industry, participated at the event, where more than 850 exhibitors and almost 35,000 attendees gathered to view an impressive display of digital manufacturing capabilities.
SGLB chief technology officer Darren Beckett demonstrated the company’s proprietary PrintRite3D(R) Real-Time Melt Pool Analytics software platform at the premier global exhibition and conference (http://nnw.fm/mV8Dm). Renowned for showcasing the next generation of intelligent industrial products, Formnext was the perfect forum to shine a worldwide spotlight on Sigma Labs’ latest PrintRite3D offering.
PrintRite3D version 5.2 contains new features and enhancements that further strengthen the usability and capabilities of the software to support the industrialization of additive manufacturing for serialized production. PrintRite3D’s new features include the following:
- Automated anomaly detection with Z connectivity, which identifies thermal anomalies that propagate across multiple layers
- Enhanced detail data trend analysis
- Customizable thresholding to enable automatic user alerts
- Real time user alert notifications for identified thermal anomalies exceeding specification limits
At Formnext 2019, Beckett presented several live demonstrations of PrintRite3D to industry executives attending the prestigious event. Beckett was also available for technical reviews.
“This leading industry event for additive manufacturing and modern industrial production grows every year, clearly demonstrating the elevated interest and new opportunities ahead in additive manufacturing,” Beckett said. “It’s an exciting time for Sigma Labs as a leader in the field.”
Formnext 2019 is a leading global trade fair dedicated to additive manufacturing and industrial 3D printing. The Frankfurt event brought together the industry’s elite from 34 nations. SGLB was able to reach market leaders such as, Materialise, Additive Industries, Addup, DMG Mori, EOS, GE, Materialise, Matsuura, , Renishaw, Siemens, SLM Solutions, Trumpf, Panasonic, Mitsubishi, United Technologies, Rosswag, Volkswagen, Fraunhofer, BASF, Safran, Baker Hughes, GKN, Stryker, Coherent Laser, Oerlikon, Airbus, Nikon, Zeiss and many more.
Formnext functions as a significant business platform for industry players at which many companies conduct concrete business transactions directly on the exhibition floor (http://nnw.fm/Bhy0I). As the growing additive manufacturing industry continues to evolve, it is likewise attracting a growing number of investors. At Formnext 2019, “there was a significant increase in interest from venture capital companies and industrial companies who, for example, would like to become strategic partners for young companies.”
Sigma Labs Inc. is a leading provider of quality assurance software to the commercial 3D-printing industry under the PrintRite3D brand. Founded in 2010, Sigma is a software company that specializes in the development and commercialization of real-time, computer-aided inspection solutions for 3D advanced manufacturing technologies. Sigma Labs’ advanced computer-aided software product revolutionizes commercial additive manufacturing, enabling nondestructive quality assurance mid-production, thereby allowing errors to be corrected in real time.
For more information, visit the company’s website at www.SigmaLabsInc.com
NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://nnw.fm/SGLB
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
December 10, 2019
Palm Beach, FL – December 10, 2019 – It seems that every new report on projected revenues in the cannabis markets, global and U.S and North America, all seem to agree on one thing: The cannabidiol (CBD) revolution will continue to rise. An industry insider, Technavio, who has been monitoring the global cannabis-infused edible products market, recently projected that the market is poised to grow by USD $17.27 billion during 2018-2022 at a CAGR of over 25% during the forecast period. The market is driven by the growing social acceptance of cannabis. In addition, the increasing number of countries decriminalizing cannabis is anticipated to further boost the growth of the cannabis-infused edible products market. As consumers accept… and even demand more CBD products, the future is projected to continue to rise in years to come. The Technavio report said: “The cannabis industry has emerged as lucrative business segment with immense potential for market growth and is attracting many new vendors and large investors. This is due to the increasing social acceptance of recreational marijuana and cannabis-infused edible products across different regions. This has not only increased the sales and revenues of major corporations but has also significantly added to the income of several governments. Vendors are witnessing an increase in the growth opportunities in businesses involving cannabis-infused edible products such as brownies, ice creams, and chocolates. Thus, the growing social acceptance of cannabis is expected to drive market growth during the forecast period.” Active Companies from around the market with current developments this week include: Singlepoint, Inc. (OTCQB: SING), Medical Marijuana, Inc. (OTCPK: MJNA), mCig, Inc. (OTCPK: MCIG), Canopy Growth Corporation (NYSE: CGC) (TSX: WEED), The Green Organic Dutchman Holdings Ltd. (OTCQX: TGODF) (TSX: TGOD).
Additionally a report from Statista has reported that it expects that U.S. consumer sales of CBD will reach around $1.8 billion U.S. dollars by 2022. That would be a massive increase from around half a billion dollars in 2018. Thus, the CBD consumer market is following the trend of the total legal cannabis market in the U.S., which is projected to be a 23-billion-dollar business by 2025.
Singlepoint, Inc. (OTCQB: SING) BREAKING NEWS: SinglePoint Announces Distributor Agreement with JTI USA – Singlepoint announces a new distribution agreement that allows for the expanded footprint of PrimeTime little cigars in North America and will be attending the 2019 MJBIZCON show in Las Vegas December 11-13 booth number C9132. The company recently signed on as a distributor for JTI USA, part of the JT Group of companies, a multibillion-dollar organization with international presence in 130 countries. Initially, SinglePoint will start out by supporting to further drive the distribution and sales of PrimeTime Little Cigars.
Distributors and Retailers interested in carrying these innovative products please call 855-203-3318
“We are excited to be working with SinglePoint. SinglePoint CEO Mr. Lambrechts’ prior experience in distribution of premium cigars, we believe will lead to continued growth of JTI USA products and the PrimeTime™ brand”, states Renee Duszynski Director of Sales JTI.
SinglePoint will commence sales and take orders for JTI’s “PrimeTime Little Cigars” at the 2019 MJBIZCON being held at the Las Vegas Convention Center, December 11, 12 and 13.
“I’m excited and honored to be working with JTI to distribute PrimeTime Little Cigars… The opportunity to work with a global leader in this category is exciting and we are ready to expand Primetime’s U.S. market share with our unique experience in alternative markets. Having placed premium cigars in over 30,000 accounts, we expect this opportunity to be one of our major revenue sources in coming years, and to distribute additional JTI products as we grow this category”, says Greg Lambrecht, CEO SinglePoint.”
PrimeTime Little Cigars are known as “The best flavored little cigars on the market” available in many flavors such as: Cherry, Grape, Vanilla, Peach and more. This tobacco product line offers a great alternative to cost conscious adult smokers, looking for a quality product.
“Innovation has always been central to what JTI does…For example, PrimeTime has the only encapsulation machine that can manufacture and package individual PrimeTime Little Cigars,”, Lambrecht says. Read this and more news for SING at: https://www.financialnewsmedia.com/news-sing
In the industry developments and happenings in the market this week include:
Medical Marijuana, Inc. (OTCPK: MJNA), the first-ever publicly traded cannabis company in the United States that launched the world’s first-ever cannabis-derived nutraceutical products, brands and supply chain, recently announced that subsidiary HempMeds® Brasil applauds ANVISA (the National Agency for Health Supervision) for unanimously approving the regulation of medical marijuana to be sold at pharmacies and drugstores nationwide. Brazil’s new regulations will be published soon on the Federal Official Gazette and entered into law 90 days after that.
“These new regulations to allow the rollout of cannabis products in pharmacies and drugstores create a new category of medicinal cannabis products in Brazil,” said HempMeds® Brasil Vice President Caroline Heinz. “This change will allow patients almost immediate access to CBD products – a huge difference from today where the process takes three months. The approximate four million patients in Brazil can benefit from medical cannabis much easier with the ability to visit their doctor’s office and go directly to a pharmacy. We hope that this will encourage more people to see how cannabis could help improve their health and wellness.”
mCig, Inc. (OTCPK: MCIG). a company focusing on the marketing, sale, and distribution of CBD products, recently announced that it has entered into a binding letter of intent (“LOI”) to create a joint venture with Bare Roots Rx LLC., a leading supplier of high quality, organic botanical CBD products.
Under terms of this agreement, mCig will own 51% of the joint venture in exchange for marketing support, new sales channels, technical support and much needed equipment. Bare Roots Rx has current revenue of approximately $1M and pending orders for 2020 far in excess of current levels. The new Joint Venture will operate two distinct divisions: health care space and consumer products. These divisions will be supported by a medical and scientific advisory board.
Canopy Growth Corporation (NYSE: CGC) (TSX: WEED) recently officially revealed its Cannabis 2.0 portfolioof products last week, set to come to market as part of the second wave of Canadian cannabis commercialization. With December 16, 2019, being the first date new product formats can be sold into distribution channels, the Company expects that in most markets new products will not be seen on shelves until early in January 2020. Leveraging learnings from Cannabis 1.0, the Company will stagger its launch of various products and formats to ensure a smooth roll-out. As such, availability will vary by province based on their individual ordering and distribution activities. While the Company is providing this update in advance of the launch of Cannabis 2.0 products, for competitive reasons, it will not provide ongoing updates during the actual rollout period.
The Green Organic Dutchman Holdings Ltd. (OTCQX: TGODF) (TSX: TGOD.TO), a leading producer of premium certified organic cannabis, recently announced that it has received its inaugural purchase order from the BC Liquor Distribution Branch (“BCLDB”), further expanding its Canadian distribution footprint. The Company also obtained a licence amendment from Health Canada, allowing it to launch cultivation operations at its flagship Valleyfield hybrid greenhouse.
The addition of British Columbia means that TGOD now has the ability to distribute its products to a total of 527 retail locations across five provinces, or 82% of Canada’s current store count. With the number of cannabis stores poised to increase from 639 to over a thousand in 2020, the Company is continuing to strategically develop and nurture solid relationships with provincial boards and retailers, cementing its position as the leading certified organic brand.
DISCLAIMER: FN Media Group LLC (FNM), which owns and operates Financialnewsmedia.com and MarketNewsUpdates.com, is a third party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated in any manner with any company mentioned herein. FNM and its affiliated companies are a news dissemination solutions provider and are NOT a registered broker/dealer/analyst/adviser, holds no investment licenses and may NOT sell, offer to sell or offer to buy any security. FNM’s market updates, news alerts and corporate profiles are NOT a solicitation or recommendation to buy, sell or hold securities. The material in this release is intended to be strictly informational and is NEVER to be construed or interpreted as research material. All readers are strongly urged to perform research and due diligence on their own and consult a licensed financial professional before considering any level of investing in stocks. All material included herein is republished content and details which were previously disseminated by the companies mentioned in this release. FNM is not liable for any investment decisions by its readers or subscribers. Investors are cautioned that they may lose all or a portion of their investment when investing in stocks. For current services performed FNM expects to be compensated twenty three hundred dollars for news coverage of the current press release issued by Singlepoint, Inc. by a non affiliated third party. FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and FNM undertakes no obligation to update such statements.
Contact Information:
Media Contact email: editor@financialnewsmedia.com – +1(561)325-8757
December 10, 2019
In Michigan, recreational marijuana business is booming. On Wednesday, a recorded message from Arbors Wellness in Ann Arbor said that currently, the shop has a high number of customers, which is keeping them extra busy and they are therefore unable to answer calls. The overwhelming demand has even led to purchase limits being imposed by the retailers.
The sale of recreational marijuana in Michigan was launched on December 1 and since then, demand has been so high that businesses were forced to turn away customers at some point. On the first day of recreational sales, four shops generated an average of $221,000.
On Wednesday, Arbor Wellness owner, James Daly, said that they had a line of customers all day and that they are working through the lines professionally with a wait time of approximately 40 minutes.
Greenstone Provisions in Ann Arbor employees said that by 1 pm on Wednesday, the wait time to get served was about 2-hours. While on Tuesday, customers had to wait for 3 to 4-hours before getting served at Exclusive Brand’s dispensary in Ann Arbor.
Michigan Supply and Provisions in Morenci, located along the border with Ohio, is having a steady flow of customers; however, on Wednesday afternoon, no customers were waiting in line to be served.
On Sunday and Monday, Greenstone Provisions had to turn away hundreds of potential customers because it had run out of stock of marijuana buds. Since then, the retail outlets made a point of restocking daily.
Marijuana shops have been forced to institute a purchase cap on the amount of marijuana each individual is supposed to buy because of the massive demand. Greenstone Provisions, Michigan Supply, and Provisions in Morenci have instituted a sale limit of 7 grams of marijuana flower per person.
Arbor Wellness’ sale limit is 1/8 of an ounce of flower. They also have a purchase limit of two edibles, seven pre-rolled joints, and 15 vaping cartridges.
The only dispensary that did not institute purchasing caps is Exclusive Brands. On Wednesday, Omar Hishmesh, Exclusive Brands co-owner, said that they are not putting any sale limit since they are not going to run out of stock. He further noted that they are fully stocked and are actively re-stocking products; thus, no shortages.
According to Michigan laws, the sale limit for the flower is 2.5 ounces, which includes a maximum of 15 grams of concentrate.
In-store inventory is moving like a hotcake, which makes real-time resupplying difficult; however, business owners still insist product shortages will not happen any time soon.
Currently, there are three licensed recreational marijuana processing plants and one licensed transportation business in Michigan.
Greenstone Provisions and Michigan Supply and Provisions inventory is at the mercy of their competition since the three licensed processing facilities are owned by their competitors. The three facilities are owned by Exclusive Brands, Arbor Wellness, and Green Peak. Green Peak is the largest processing facility in Michigan, and it is planning on establishing retail locations across the state.
It would be interesting to hear what cannabis companies, such as Green Growth Brands Inc. (CSE: GGB) (OTCQB: GGBXF) and Grapefruit Boulevard Investments Inc. (OTCQB: IGNG), have to say about how things are looking up for the industry in Michigan.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
December 10, 2019
FN Media Group Presents Potstocknews.com Market Commentary
New York, NY – December 10, 2019 – There’s no hiding the fact that the legal recreational pot industry has underperformed. Challenges primarily at the retail level—such as a lack of dispensaries, unnecessarily burdensome regulations, and a rapid erosion of investor trust—have led the pot space to fall short of reaching its full potential. Investors can’t be blamed for feeling hesitant to put money on pot stocks, but the hardship that the industry currently faces does not indicate that the market should be abandoned. In fact, the potential for adult-use recreational pot is still high, the pay-off has simply been delayed. This last year lacked most of the catalysts that investors were relying on to kick the industry into gear, but many of them will arrive in 2020. Until then, the market is undergoing a period of correction that will “weed out” the truly underperforming companies from the ones that can deliver. By studying the moves of pot companies that have spent 2019 investing in growth and future business strategies, we can find the pot stocks that are positioned to dominate the space in the coming years. Specifically, companies like Meta Growth Corp. (TSXV:META), OrganiGram Holdings (TSX:OGI) (NASDAQ:OGI), Fire & Flower Holdings Corp (TSX:FAF) (OTCPK:FFLWF), Supreme Cannabis Company (TSX:FIRE) (OTCQX:SPRWF) and Aphria Inc (TSX:APHA) (NYSE:APHA) are positioned to grow rapidly in the near term and flourish in the long term.
The Industry is Turning Around
Factors expected to drive growth over the next few years include the arrival of edibles, beverages, and vaping products, as well as greater education and awareness of the benefits of CBD products will also expand the consumer base. Also, as the legalization movement gains traction in the US—thanks to the momentum of things like the MORE Act—investors will return to pot stocks with even more vigor than before.
Bethany Gomez, managing director of Brightfield Group, says that an “adjustment” will occur which will get the recreational pot industry back on track. This adjustment will involve some companies losing value and potentially going under. But those that survive will ultimately thrive, and, with less competition, will enjoy a greater share of the market.
“The good thing is, Canada has one of the highest [pot] usage rates in the world—so it’s going to be a longer play,” said Gomez.
According to a study conducted by FTI Consulting Inc.—who spoke with 660 retail investors with at least $250,000 in investable assets—79% of Canadians and 74% of Americans still find the pot retail industry appealing.
The only question that remains is, which companies will stick around long enough to benefit from this longer term play? To answer that, it’s necessary to look at companies that have spent the first year of legalization focusing on growth and readying themselves for the coming boom.
Meta Growth is Going Above and Beyond
Until recently, Meta Growth Corp. (TSXV:META) was known as National Access Cannabis. According to the company, the name change—which aligns its corporate and retail brands, as well as its stock ticker—reflects its intention to become “the preeminent pot retailer in Canada.”
As part of its rebranding, Meta Growth is selling its portfolio of medical pot clinics, expecting to raise $4 million which will be used to fund the buildout of recreational pot retail stores.
“As the industry has evolved, our focus has shifted from medicinal to recreational [pot], and today, retail is our portfolio and our future,” said CEO Mark Goliger. “Brand recognition and consistency are key to our success and META is ready to continue to maintain our leadership position in the Canadian retail market.”
The potential for recreational pot is clear. Of the $5.2 billion USD that will be spent on Canadian pot by 2024, 92% of it—or roughly $4.8 billion—will go towards the recreational sector. And, as Goliger said, Meta Growth is already a leader there.
According to a press release from mid-October, in the first year following federal legalization, Meta Growth Corp. (TSXV:META) has made over $60 million in retail sales at a cumulative gross margin of 32%. This allows the company to claim the title of Canada’s “largest publicly traded recreational [pot] retailer by revenue,” and makes it one of the fastest growing and largest revenue generators in the entire Canadian industry.
This positions the company as perhaps investors’ best chance to capitalize on the long-awaited pot boom. Not only has META proven it can earn serious revenue, it can also leverage all the data gleaned from millions of customer interactions in order to better access consumers and develop long-term customer loyalty.
In coordination with its growing revenue and customer base, the company is also expanding its retail footprint across Canada. It currently has 35 licensed stores in the country, and plans to have 95 stores operating by the end of calendar 2020.
Given the progress of Meta Growth Corp.’s (META.V) sales, community, and retail reach, there’s little reason to doubt that it will make good on its intention to become Canada’s leading pot retailer in time to capitalize on the industry’s value maturation.
Other Companies Investors Should Consider
According to its Q4 2019 fiscal results released at the end of November, OrganiGram Holdings (TSX:OGI) (NASDAQ:OGI), the company’s net revenue for 2019 grew 547% year-over-year. It also became one of the first pot companies to post a positive adjusted EBITDA, putting it in a highly enviable position in the industry.
Much like Meta Growth Corp. (META.V), Fire & Flower Holdings Corp (TSX:FAF) (OTCPK:FFLWF) has focused on growing its retail footprint in the Canadian prairies. On November 26 it announced the opening of its 34th, 35th, and 36th dispensaries. By the end of its fiscal year in February, it plans to have 45 stores in total.
On the production side of the supply chain, the Supreme Cannabis Company (TSX:FIRE) (OTCQX:SPRWF) recently expanded its manufacturing capacity with a 107,000 square foot central processing facility in Ontario. In addition, having received the proper license amendment last month, its Blissco facility will begin filling and packaging vaporizer pods for Pax Labs, makers of the best-selling pen-and-pod system in the US.
Finally, Aphria Inc (TSX:APHA) (NYSE:APHA) is perhaps the best-funded company in the recreational pot space. Likewise, it’s predicting the highest revenues for the coming year. In its Q1 2020 earnings, Aphria forecast net revenue between $650 million and $700 million, with
adjusted EBITDA of approximately $88 million to $95 million.
What Investors Can Expect from Pot in 2020
When analysts at BDS Analytics cut value estimates on Canada’s recreational pot market from $5.9 billion USD by 2022 to $5.2 billion USD by 2024, many saw it as a repudiation of the “green rush.” In reality, it only pushed the true green rush just a little further down the road.
The estimate was cut due to the poor roll-out of legalization, not because the market itself lacks the potential that analysts first identified. Over the next five years, the market will be growing at a compound annual growth rate of 44%.
For Meta Growth Corp. (META.V) this presents a clear window for capitalization. The company’s capital raised from selling its medical clinics—as well as its revenue growth in excess of 3,000% year-over-year—will serve as a springboard for its expanded retail footprint. With 95 stores expected to be open across Canada by the end of 2020, it will be incredibly well positioned to capture a sizable portion of the multi-billion dollar market.
Among META’s competitors, OrganiGram Holdings is making some of the most revenue-forward moves in the industry, posting positive adjusted EBITDA while many recreational pot companies are still struggling to break even. Fire & Flower Holdings Corp has also been growing its retail footprint, and now has roughly the same amount of dispensaries as Meta. It’s ambitions for future growth, however, are more conservative.
For production, the Supreme Cannabis Company) is ensuring it’s well-positioned to supply pot products through its newfound facilities. Meanwhile, Aphria Inc) is projecting unprecedented revenue growth in the coming year, and is financed to ensure it makes good on its forecast.
These five companies are making the exact moves needed to not only survive in the recreational pot industry, but to control it in just a few years’ time. Investors looking to make a pot play should consider Meta Growth Corp. (TSXV:META) and its contemporaries first and foremost as the market finally delivers on the lucrative promises of the “green rush.”
For a FREE research report on Meta Growth Corp (TSXV:META) visit PotStockNews.com.
Disclaimer: Potstocknews.com (PSN) is the source of the Article and content set forth above. References to any issuer other than the profiled issuer are intended solely to identify industry participants and do not constitute an endorsement of any issuer and do not constitute a comparison to the profiled issuer. FN Media Group (FNM) is a third-party publisher and news dissemination service provider, which disseminates electronic information through multiple online media channels. FNM is NOT affiliated with PSN or any company mentioned herein. The commentary, views and opinions expressed in this release by PSN are solely those of PSN and are not shared by and do not reflect in any manner the views or opinions of FNM. Readers of this Article and content agree that they cannot and will not seek to hold liable PSN and FNM for any investment decisions by their readers or subscribers. PSN and FNM and their respective affiliated companies are a news dissemination and financial marketing solutions provider and are NOT registered broker-dealers/analysts/investment advisers, hold no investment licenses and may NOT sell, offer to sell or offer to buy any security.
The Article and content related to the profiled company represent the personal and subjective views of the Author (PSN), and are subject to change at any time without notice. The information provided in the Article and the content has been obtained from sources which the Author believes to be reliable. However, the Author (PSN) has not independently verified or otherwise investigated all such information. None of the Author, PSN, FNM, or any of their respective affiliates, guarantee the accuracy or completeness of any such information. This Article and content are not, and should not be regarded as investment advice or as a recommendation regarding any particular security or course of action; readers are strongly urged to speak with their own investment advisor and review all of the profiled issuer’s filings made with the Securities and Exchange Commission before making any investment decisions and should understand the risks associated with an investment in the profiled issuer’s securities, including, but not limited to, the complete loss of your investment. FNM was not compensated by any public company mentioned herein to disseminate this press release but was compensated twenty five hundred dollars by PSN, a non-affiliated third party to distribute this release on behalf of Meta Growth Corp.
FNM HOLDS NO SHARES OF ANY COMPANY NAMED IN THIS RELEASE.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected,” “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and PSN and FNM undertake no obligation to update such statements.
Media Contact:
FN Media Group, LLC
info@financialnewsmedia.com
+1(561)325-8757
Youngevity International (NASDAQ: YGYI), a leading omni-direct lifestyle company, this morning announced that it will be presenting at the 12th annual LD Micro Main Event on Wednesday, December 11 at 11:20 AM PST. YGYI president and CFO Dave Briskie will be presenting in front of a variety of institutional investors, family offices, and high net worth investors. In addition, Youngevity will serve as a premier sponsor of the event featuring Be the Change(TM) coffee and Josies Java House Coffee, two of the company owned brands. “LD Micro continues to be an integral part of our awareness campaign and we are proud to be a premier sponsor, once again, for this year’s Main Event,” Youngevity president and CFO Dave Briskie stated in the news release. The Youngevity presentation will be available for 90 days following the live presentation (http://cnw.fm/CaTH2).
In addition, YGYI’s wholly-owned subsidiary, Khrysos Industries, Inc., this morning announced its participation as a lead sponsor at MJ Biz Con, the largest USA-based cannabis conference, which will take place in the Las Vegas Convention Center on December 11, 12, and 13. As a sponsor, Khrysos will feature a digital marketing piece that will be played on 12 screens 48 times a day. The conference is expected to draw an attendance of over 35,000 people from more than 70 countries including 1,500 CEO’s, 8,000 industry high level executives, and an expected attendance of over 1,250 cannabis industry investors. “We are proud to be sponsoring the MJ Biz Con conference this year,” Khrysos Industries president Dwayne Dundore PhD stated in the news release. “We will have our high-speed filtration systems, our KG250 hyper supercritical Co2 extraction system, a dual flask 50L rotary evaporator with HMI, a single stage stainless steel molecular wiped film distillation system and welch pumps and various displays featuring the capabilities of our vertical operation.”
To view the full press release, visit http://cnw.fm/K9SfV and http://cnw.fm/4nPgP
About Youngevity International Inc.
YGYI, Inc. (NASDAQ: YGYI), is a leading omni-direct lifestyle company offering a hybrid of the direct selling business model, that also offers e-commerce and the power of social selling. Assembling a virtual Main Street of products and services under one corporate entity, YGYI offers products from the eight top-selling retail categories: health/nutrition, home/family, food/beverage (including coffee), spa/beauty, fashion, essential oils, photo, as well as innovative services. The company was formed in the course of the summer 2011 merger of Youngevity Essential Life Sciences with Javalution(R) Coffee company (now part of the company’s food and beverage division). The resulting company became Youngevity International, Inc. in July 2013. For investor information, please visit www.YGYI.com.
NOTE TO INVESTORS: The latest news and updates relating to YGYI are available in the company’s newsroom at http://cnw.fm/YGYI
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
December 10, 2019
- Software pioneer Sigma Labs’ offers first known, real-time, computer-aided inspection (CAI) technology that enables in-process intervention
- PrintRite3D overcomes quality assurance obstacles that hinder 3D metal printing from becoming fully integrated into modern manufacturing lines
- Sigma Labs’ PrintRite3D enables real-time monitoring, analysis, feedback and control during the 3D-printing process of precision metal parts
Sigma Labs Inc. (NASDAQ: SGLB) is a leading producer of quality assurance software for the commercial 3D-printing industry. The company is about to revolutionize commercial 3D printing metal by enabling nondestructive quality assurance during the production process. Sigma Labs’ proprietary PrintRite3D software is a real-time, computer-aided inspection (CAI) technology long sought by 3D printing companies to lower costs and increase yields. PrintRite3D represents a breakthrough in the 3D-quality inspection sphere because it is the only known real-time, in-process, quality-assurance software for the commercial 3D metal printing industry.
3D printing, also called additive manufacturing, is a technology that allows producers to transform a 3D digital model of an object into a physical one by adding material rather than subtracting it, hence the additive in the name. The resulting 3D objects are made in a digitally controlled and operated process by depositing minuscule layers of material onto a substrate layer.
The technology has been embraced by commercial users, especially aerospace. The technology allows companies to build digital designs, push ‘Send’ and render fully formed prototype, customized products or commercial parts in volume – all while saving money, manpower, weight and time. However, the technology is facing hurdles in finding its way beyond prototyping and into conventional manufacturing and serial production. The reason? Before 3D printing metal can be fully integrated into modern manufacturing lines, technology is needed to resolve significant issues such as optimized data handling as well as real-time quality assurance process, monitoring and control.
Due to variances in the 3D-printing process, consistent quality of produced parts can’t be reliably achieved without considerable postproduction inspection that results in high rejection costs. Because parts are inspected after production using expensive CT scans, the manufacturer doesn’t know until the end of the process which of the finished parts meet design specifications. This results in lost time, lost profits and inability to economically scale up production.
This is where Sigma Labs steps in. The company’s people, processes and technologies are pioneers, about to transform the nascent 3D-printing sector by enabling SGLB’s rapid, efficient commercial applications and allowing growth at scale. Unlike any other quality-inspection software in the market, PrintRite3D is a third-party, validated software that enables real-time monitoring, analysis, feedback and control during the 3D-printing process of precision metal parts. The software conducts thermal-signature anomaly detection and automatic risk-level classification through statistical process sampling and advanced analytics.
This innovative solution is based on a proactive, comprehensive, process-focused methodology that enables prediction of product conformance to predefined acceptance requirements. More simply, PrintRite3D discovers defects during the production while adjusting the process in real-time to correct them. This unique solution leads to faster production of metal parts with fewer errors and a more uniform product resulting in decreasing downtime and waste while increasing yield and profits for 3D-printing companies.
3D printing is an innovative technology that has seen growing interest from manufacturers and investors alike stemming from decreasing product lifecycles trend, which is influenced by factors such as increased global competition and the need for innovation due to saturated markets and changing customer demands. Additive-manufacturing technology is viewed as a response to these challenges as it considerably reduces time to market.
According to Verified Market Research, the global 3D-printing market was valued at $8.08 billion in 2017 and is expected to grow at a CAGR of 25.5% from 2018 to 2025, reaching the value of $49.74 billion (http://nnw.fm/Hw0fh). Given these impressive growth rates, investors have been investing heavily in 3D-printing companies now that their commercial applications are soaring. The sector has already produced three unicorns, with the highest valued being Carbon, a 3D-printing, venture-backed startup that has raised $680 million, at a valuation of $2.4 billion, from investors such as Sequoia Capital, Madrone, Baillie Gifford Capital Partners and GV.
Sigma Labs was founded in 2010 and has since become the go-to, 3D-printing expert for real-time, computer-aided inspection (CAI) solutions. Managed by experts from many different science disciplines such as metallurgy, physics, signal processing, mechanical engineering, optics, software AI and ML, data analytics and visualization, the company established credibility within highly demanding industries such as aerospace, defense, biomedical and transportation.
For more information, visit the company’s website at www.SigmaLabsInc.com
NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://nnw.fm/SGLB
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
December 9, 2019
On Tuesday, the residents of New Zealand got a peek at the contents of a draft proposal on marijuana legalization that will be subject to a voter’s decision during the 2020 ballot.
According to a summary statement, the government of New Zealand is publishing the draft bill to ensure that the residents are well informed on the direction of legalization and the decisions being made.
The draft legislation gives a framework of the essential elements of establishing a regulated recreational marijuana market. Before the 2020 elections, the government will have updated the bill while taking into account public feedback.
If the bill is voted for by more than 50% of all voters, the soon to be elected government will have the responsibility of enacting new laws for regulating recreational marijuana.
The proposed legislation has the following policies:
- People above the age of 20 would be able to purchase marijuana products.
- People would be required to consume weed in private places and licensed facilities.
- Mandate investments in public health education campaigns.
- It would impose restrictions on campaigns.
- It would also create a marijuana business licensing program.
- People are also allowed to purchase up to 14 grams of marijuana per day and grow a maximum of two plants for personal use.
The government of New Zealand would be tasked with the establishment of the Cannabis Regulatory Authority to regulate the marijuana industry, approve business permits, and promote public health. The Cannabis Regulatory Authority would also be responsible for imposing the excise tax so that the government can recover costs incurred during the implementation of the marijuana program.
In a press release, Justice Minister Andrew Little said that the purpose of making the referendum questions, Marijuana Legalization draft and the Control Bill was to promote public awareness and discussions.
He further said that he aims to have the draft bill published in early 2020, to give them time to debate any needed changes. He also said that experience from abroad shows them the importance of presenting the public with factual and explanatory information to make an informed decision when voting.
The primary objectives of the legislation are to promote policies that reduce the severity of harm associated with marijuana and reduce the rate of marijuana use through education and treatment programs. The bill’s secondary objective is to eliminate the black market, reduce the arrest record, and safeguard quality control for marijuana products.
The details on the legalization proposal were first published in May. The bill was approved for a voter’s decision after the Green Party struck a deal to install Labor Party head Jacinda Ardern as the prime minister.
The referendum question will be structured like this:
- Do you support the proposed Cannabis Legalization and Control Bill?
- YES, I support the proposed Cannabis Legalization and Control Bill.
- No, I do not support the proposed Cannabis Legalization and Control Bill.
This week, a survey was released showing that 49% of New Zealand residents are opposed to marijuana legalization, and 43% support marijuana reform. It is uncertain if the voters will give the bill the nod.
Green Party MP, Chloe Swarbrick, said that the primary focus of the bill is to limit access, and eradicate the illicit market. Swarbrick further noted that in New Zealand, people of all ages could purchase weed since the drug dealers do not check IDs, nor do they care about the safety of the products they are selling.
Analysts think marijuana industry players like Canopy Rivers Inc. (TSX.V: RIV) (OTC: CNPOF) and ChineseInvestors.com Inc. (OTCQB: CIIX) hope that the winds of change blowing offshore also prevail on the U.S. federal government to revisit its marijuana policies.
About CNW420
CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CNW420.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW420? Ask our Editor
CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CNW420 is part of the InvestorBrandNetwork.
Predictive Oncology (NASDAQ: POAI), a data and artificial intelligence (“AI”) driven discovery services company that provides predictive models of tumor drug response to improve clinical outcomes for patients, today announced updates on the commercialization of its CancerQuest 2020 initiative. According to the update, the Company is confident that its first predictive model of ovarian cancer will be ready for initial commercialization in revenue generating projects with Pharma in the first quarter of 2020. Predictive Oncology’s Helomics division has been working closely with its sequencing partner to optimize and scale the generation of both genomic and transcriptomic data and has sequenced the first batch of ovarian tumors. The Company anticipates that the sequencing of the remainder of the 400 ovarian cancer subjects will proceed as planned, establishing another milestone in its CancerQuest 2020 initiative and path to commercialization.
To view the full press release, visit http://nnw.fm/5d3BI
About Predictive Oncology Inc.
Predictive Oncology (NASDAQ: POAI) operates through five segments (Domestic, International, Clinical, CRO and DCHIP), which contain four subsidiaries; Helomics, TumorGenesis, Skyline Medical and Skyline Europe. Helomics applies artificial intelligence to its rich data gathered from patient tumors to both personalize cancer therapies for patients and drive the development of new targeted therapies in collaborations with pharmaceutical companies. Helomics’ CLIA-certified lab provides clinical testing that assists oncologists in individualizing patient treatment decisions, by providing an evidence-based roadmap for therapy. In addition to its proprietary precision oncology platform, Helomics offers boutique CRO services that leverage its TruTumor(TM), patient-derived tumor models coupled to a wide range of multi-omics assays (genomics, proteomics and biochemical), and an AI-powered proprietary bioinformatics platform (D- CHIP) to provide a tailored solution to its clients’ specific needs. Predictive Oncology’s TumorGenesis subsidiary is developing a new rapid approach to growing tumors in the laboratory, which essentially “fools” cancer cells into thinking they are still growing inside a patient. Its proprietary Oncology Discovery Technology Platform kits will assist researchers and clinicians to identify which cancer cells bind to specific biomarkers. Once the biomarkers are identified they can be used in TumorGenesis’ Oncology Capture Technology Platforms which isolate and help categorize an individual patient’s heterogeneous tumor samples to enable the development of patient specific treatment options. Helomics and TumorGenesis are focused on ovarian cancer. Predictive Oncology’s Skyline Medical division markets its patented and FDA cleared STREAMWAY System, which automates the collection, measurement and disposal of waste fluid, including blood, irrigation fluid and others, within a medical facility, through both domestic and international divisions. The company has achieved sales in five of the seven continents through both direct sales and distributor partners. For more information, please visit www.Predictive-Oncology.com.
NOTE TO INVESTORS: The latest news and updates relating to POAI are available in the company’s newsroom at http://nnw.fm/POAI
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
December 9, 2019
- Sigma Labs proprietary software featured at major global 3D-printing conference
- Presentation showcased version 5.2 of the software, which features several software enhancements
- Partnership validates Sigma Labs’ software as a leading additive-manufacturing solution
Sigma Labs Inc. (NASDAQ: SGLB), a leading producer of quality-assurance software for the commercial 3D-printing industry, demonstrated the latest version of its proprietary technology PrintRite3D(R) in collaboration with Materialise NV at the Formnext 2019 conference held in Frankfurt, Germany, on November 19-22.
As a pioneer in the 3D-printing, quality-assurance domain, Sigma Labs partnered with Materialise, one of the most innovative developers of additive-manufacturing software and printing solutions. The two companies joined forces to integrate their innovative technologies in response to the growing need for more control and increased productivity in 3D printing, which should enable broader adoption and scalability of additive manufacturing. Combining Sigma Labs’ advanced quality-control technology with in-situ process monitoring for metal 3D printing will give customers maximal control of the production process.
Formnext is the premier global exhibition and conference dedicated to 3D printing and the next generation of intelligent industrial production. During the three-day event, experts from a wide range of industries such as aerospace, mechanical engineering, automotive, electrical engineering and medical technology gathered to discover and explore advancements in additive manufacturing, industrial 3D printing and related upstream and downstream processes.
At the event, Sigma Labs’ chief technology officer Darren Beckett presented on “The Integration of PrintRite3D Melt Pool Monitoring Software with Materialise’s Machine Control Platform (MCP) for Advanced Process Control.” The presentation showcased version 5.2 of the software, which features several software enhancements including the automated anomaly detection with Z connectivity that identifies thermal defects which propagate across multiple layers and enhanced data-trend analysis and customizable thresholding that enable automatic alerts. These new functionalities should further strengthen the capabilities of additive manufacturing for serial production.
Materialise incorporates more than 25 years of additive-manufacturing experience into a broad range of software solutions and 3D-printing services, which together form the foundation of the 3D-printing industry. Headquartered in Belgium with branches worldwide, Materialise leverages the largest group of software developers in the industry with one of the largest, global, 3D-printing facilities. Recognized as one of the prominent technology leaders in the 3D-printing space, Materialise has impacted entire industries including aerospace, health care, automotive, art and design, and consumer goods. The company recognizes PrintRite3D as the leading quality-assurance software that, when combined with Materialise Control Platform (MCP), can enable a unique, integrated product solution for volume manufacturing.
The partnership between the two companies validates Sigma Labs’ software as the leading solution for the additive-manufacturing industry, positioning Sigma labs at the forefront of the industry.
Sigma Labs was founded in 2010 and has since become the go-to, 3D-printing expert for real-time, computer-aided inspection (CAI) solutions. Managed by experts from many different science disciplines such as metallurgy, physics, signal processing, mechanical engineering, optics, software AI and ML, data analytics and visualization, the company established credibility within highly demanding industries such as aerospace, defense, biomedical and transportation.
For more information, visit the company’s website at www.SigmaLabsInc.com
NOTE TO INVESTORS: The latest news and updates relating to SGLB are available in the company’s newsroom at http://nnw.fm/SGLB
About NetworkNewsWire
NetworkNewsWire (NNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) NetworkNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, NNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. NNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, NNW brings its clients unparalleled visibility, recognition and brand awareness. NNW is where news, content and information converge.
To receive SMS text alerts from NetworkNewsWire, text “STOCKS” to 77948 (U.S. Mobile Phones Only)
For more information please visit https://www.NetworkNewsWire.com
Please see full terms of use and disclaimers on the NetworkNewsWire website applicable to all content provided by NNW, wherever published or re-published: http://NNW.fm/Disclaimer
NetworkNewsWire (NNW)
New York, New York
www.NetworkNewsWire.com
212.418.1217 Office
Editor@NetworkNewsWire.com
NetworkNewsWire is part of the InvestorBrandNetwork.
The Green Organic Dutchman Holdings (TSX: TGOD) (OTCQX: TGODF), a leading producer of premium, certified-organic cannabis, recently inked agreements for increased funding totaling up to $103 million. TGODF intends to utilize the capital to complete construction of various facilities and achieve national product distribution. An article discussing the company reads, “‘Our ability to raise capital, despite recent headwinds affecting the entire sector, is a clear show of confidence from our financial partners,’ TGOD CEO Brian Athaide stated in a news release. ‘It is reflective of the value of our significant assets, the trust investors are putting into TGOD’s strong corporate governance, transparency and accountability, and the opportunity for the company’s unique positioning to quickly capture and grow the organic segment.’ . . . The Green Organic Dutchman, one of the few certified-organic licensed producers in Canada, has garnered industry attention because of its ability to cultivate premium product at competitive costs, due in large part to its industry partnerships, passion for product excellence and sound governance principles. The company has accrued a significant following among cannabis enthusiasts and was recently described as one of the best licensed, Canadian, cannabis producers (http://cnw.fm/w7vSJ).”
To view the full article, visit http://cnw.fm/Z8vyA
About The Green Organic Dutchman Holdings Ltd.
The Green Organic Dutchman (TSX: TGOD) (OTCQX: TGODF) is a premium, certified-organic cannabis company focused on the health and wellness market. Its certified-organic cannabis is grown in living soil, as nature intended. The company is committed to cultivating a better tomorrow by producing its products responsibly, with less waste and impact on the environment. Its two Canadian facilities are built to LEED certification standards, and its products are sold in recyclable packaging. In Canada, TGOD plans to expand its product portfolio by launching a series of next-generation cannabis products such as organic teas, infusers and vapes. Through its European subsidiary, HemPoland, the company also distributes premium hemp-CBD oil in Europe. By leveraging science and technology, TGOD harnesses the power of nature from seed to sale.
TGOD’s Common Shares and warrants issued under the indenture dated Nov. 1, 2017, trade on the TSX under the symbol “TGOD” and “TGOD.WT,” respectively.
For more information on The Green Organic Dutchman Holdings Ltd., please visit www.tgod.ca.
NOTE TO INVESTORS: The latest news and updates relating to TGODF are available in the company’s newsroom at http://cnw.fm/TGODF
About CannabisNewsWire
CannabisNewsWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.
To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CannabisNewsWire.com
Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer
Do you have a questions or are you interested in working with CNW? Ask our Editor
CannabisNewsWire (CNW)
Denver, Colorado
www.CannabisNewsWire.com
303.498.7722 Office
Editor@CannabisNewsWire.com
CannabisNewsWire is part of the InvestorBrandNetwork.
